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INTRODUCTION 
The formation of a new human being in the female body begins with the 
production of oocytes and ends with the miraculous event of birth. It is a 
delicately balanced process that requires the immaculate cooperation of different 
parts of the female reproductive tract – the ovaries, the fallopian tubes and the 
uterus. Unfortunately, 10% of all couples tackle with various infertility issues 
and female infertility is the cause in approximately 40% of cases, meaning that 
in these women, this fine-tuned balance and cooperation has been disturbed. 
Female infertility can be caused by impaired tubal function, ovulatory disorders, 
impaired endometrial function or endometriosis, while male infertility is mainly 
associated with abnormal semen quality. A study conducted among infertility 
treatment clinic patients in 2004–2005 allows to assume that in Estonia, the 
leading cause of female infertility is tubal factor infertility (TFI), followed by 
polycystic ovary syndrome (PCOS). This means that the main causes of female 
infertility in Estonia are due to disturbed ovarian and fallopian tube functions. 
In vitro fertilisation (IVF) treatment, where in vitro fertilised and cultured 
embryos are transferred directly to the uterus in theory helps to overcome most 
of the abovementioned problems. Unfortunately, IVF treatment is successful in 
only 1/3 of the cases, as calculated per treatment cycle. The outcome greatly 
depends on the effectiveness of controlled ovarian stimulation (COS), which in 
turn is highly dependent on how the ovaries respond to exogenous stimulation 
with follicle stimulating hormone (FSH). 
Over the years, great effort has been directed towards elucidating the molecu-
lar mechanisms behind the conditions causing female and male infertility and it 
has been concluded that individual genetic variation is definitely one of the 
factors that contributes to reduced fertility. Indeed, multiple links between 
genetic polymorphisms and infertility have been established. Individual genetic 
variation is also a good candidate for predicting natural reproductive function 
and perhaps even IVF treatment success, and recently a lot of research has 
focused on finding such genetic markers. Owing to these studies, we know now 
significantly more about the genetic background that affects fertility in humans; 
however, a lot still waits to be uncovered. Hence this study was conducted to 
add our contribution to the ever-growing pool of knowledge on (in)fertility in 
humans. 
The general objective of the current thesis was to assess the importance of 
various genetic factors in the etiology of female infertility and especially those 
conditions affecting the function of the ovaries and the fallopian tubes, more 
specifically PCOS and TFI. In addition, several genetic variants that could be 
related to ovarian function, COS and IVF treatment parameters were evaluated. 
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1.1. REVIEW OF LITERATURE 
1.1. Human reproduction: the role of the female 
Human reproduction is a delicately balanced process that, in addition to 
interindividual compatibility and collaboration, requires the immaculate 
cooperation of different parts of the female reproductive tract – the ovaries, the 
fallopian tubes and the uterus that all have a specific role in the process of 
procreation (Figure 1). The ovaries are responsible for oocyte maturation and 
ovulation, but also participate in the production of steroid and peptide hormones. 
The fallopian tubes connect the ovaries with the uterus and thus facilitate the 
transport of the sperm and the capture and transport of the oocyte. Since the 
ampullar region of the fallopian tubes is the preferred site of actual conception 
shortly after ovulation, the fallopian tubes are also responsible for providing an 
appropriate environment for early embryo development and transporting the 
developing embryo into the uterus. The developing embryo that has reached the 
uterus some four days after fertilisation embeds itself in the endometrium that 
lines the uterus and thus it is the uterus that has to provide the perfect place for 
embryo implantation and support the embryo and the placenta throughout the 










1.1.1. The ovary, folliculogenesis and the ovarian reserve 
The human ovaries are small (3–5 cm in length) paired organs in the abdominal 
cavity. The ovaries are covered by tunica albuginea, a capsule made of 
connective tissue, which in turn is covered by a single layer of simple squamous 
epithelium – the germinal epithelium. The ovarian tissue itself can be divided 
into two distinct regions – the ovarian cortex that contains the ovarian follicles at 
various developmental stages and stroma, and the medulla that is the highly 
vascular innermost zone that usually does not contain developing follicles. The 
main functions of the human ovary are the production and release of oocytes and 
the secretion of hormones and other factors necessary for follicular maturation 
and other stages of the reproductive cycle (such as endometrial receptivity and 
embryo implantation). 
According to the currently accepted concept, the human ovary contains a 
finite number of follicles established before birth (the ovarian reserve) that 
steadily decline with age and are virtually depleted by the time of the menopause 
(Wallace and Kelsey, 2010). While the number of primordial follicles is 
approximately 1–2 million at birth, only ~450 oocytes are ovulated and the rest 
(99%) go through atresia and degenerate, leaving some 1000 primordial follicles 
left by the time of the menopause (reviewed by Broekmans et al., 2009). In 
addition to the decrease in follicle quantity, the quality of the follicles and 
oocytes also decreases with age, reflected by the structural damage and 
increasing frequency of aneuploidies (Broekmans et al., 2009). The process of 
ovarian follicle maturation, also known as folliculogenesis, is the maturation of 
the ovarian follicle, which contains a developing oocyte. The process is 
controlled by endocrine, autocrine, paracrine and juxtacrine factors [inhibins, 
activins, insulin-like growth factors (IGFs), androgens, estrogens], but the main 
controllers are the two gonadotropic pituitary hormones – the follicle stimulating 
hormone (FSH) and the luteinizing hormone (LH), which act through 
corresponding receptors (FSHR and LHR, respectively). Although the initial 
recruitment of primordial follicles is mainly controlled by factors of ovarian-
origin [IGF-1, epidermal growth factor (EGF), anti-Müllerian hormone (AMH), 
etc.], the later stages are entirely dependent on the action of FSH and LH 
(reviewed by Messinis et al., 2010). The gonadotropin-releasing hormone 
(GnRH) regulates the release of both FSH and LH from the anterior pituitary. In 
the first half of the menstrual cycle (known as the follicular phase in the ovary 
and the proliferative phase in the endometrium), FSH stimulates follicle growth, 
recruitment and selection of the dominant follicle. FSH also stimulates the 
production of steroid hormones from granulosa cells (cells surrounding the 
ovum), while LH stimulates the production of androgens from theca cells (cells 
surrounding the granulosa cells), which are in turn transferred to granulosa cells 
and aromatised into estrogens under the influence of FSH (reviewed by Messinis 
et al., 2010). Estrogens consecutively provide negative feedback to the 
hypothalamus and pituitary to inhibit FSH and LH secretion. FSH levels are the 
highest in the beginning of the follicular phase, but then begin to drop as a 
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response to the inhibin B produced by small antral follicles. The follicle with an 
optimal level of FSH in the follicular fluid and an optimal number of FSHRs in 
the granulosa cells is “rescued”, while others become atretic (Messinis et al., 
2010). It is believed that serum FSH measured at the beginning of the follicular 
phase (most commonly on menstrual cycle day 3) may give some information on 
how well the hypothalamic-pituitary-ovarian axis is functioning (Barnhart and 
Osheroff, 1998). With age, the number of follicles recruited in each cycle 
decreases and consequently FSH secretion is not suppressed as efficiently, which 
leads to increased FSH levels. Hence elevated early follicular phase FSH levels 
represent a smaller ovarian reserve (Practice Committee of the American Society 
for Reproductive Medicine, 2015). 
In the second half of the follicular phase, LHRs appear on the granulosa cells 
and the follicle becomes dependent on LH. Approximately in the middle of the 
menstrual cycle, the LH levels rise sharply and trigger ovulation. After ovulation, 
during the luteal phase, LH stimulates the formation of the corpus luteum that 
produces estrogen and progesterone.  
Under hormonal orchestration, the maturing follicles go through distinct stages 
during folliculogenesis – primordial, primary, secondary, early/late tertiary (also 
known as antral follicles) and finally preovulatory (Figure 2). The number of 
antral follicles (measuring <10 mm in size) correlates best with the size of the 
remaining follicular pool (Practice Committee of the American Society for 
Reproductive Medicine, 2015). Folliculogenesis comes to an end when the 
limited number of follicles – the ovarian reserve – is virtually depleted. The 
process itself is continuous, meaning that at all times the ovary contains follicles 
in all developmental stages. A cycle ends when a mature oocyte is released 
during ovulation.  
The estrogens (estradiol and estrogen) secreted by the ovarian follicles during 
the follicular phase (corresponds to the proliferative phase of the endometrium) 
also stimulate the endometrial cells to proliferate, while in the second half of the 
menstrual cycle – the luteal phase (corresponds to the endometrial secretory 
phase) – the corpus luteum in the ovary produces progesterone that is 




Figure 2. Schematic overview of folliculogenesis in humans. Figure created using data 
from a review by Messinis and colleagues (Messinis et al., 2010). 
 
 
1.1.2. Fallopian tubes 
From a histological viewpoint, the fallopian tubes consist of four layers: serosa, 
smooth muscle layer, lamina propria and a mucosal layer that is arranged in 
complex folds. The muscle layer is responsible for the peristaltic movements of 
the tubes. The fallopian tubes are lined with ciliated epithelium that consists of 
ciliated cells and peg cells that produce tubal secretions. Similarly to the 
endometrium that lines the uterine cavity, the cells of the tubal epithelium also 
express receptors for estradiol and progesterone and the expression of these 
receptors is dependent upon the menstrual cycle phase (Shah et al., 1999) that 
modulates the number and functioning of epithelial cells. 
As mentioned above, one of the main functions of the fallopian tubes is tubal 
transport, which is influenced by tubal contractions, ciliary beating and tubal 
secretion flow that need to work in a well-coordinated manner to capture the 
ovulated oocyte, direct the sperm to the oocyte and finally transport the embryo 
into the uterus, where the developing embryo (hopefully) implants (reviewed by 
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Lyons et al., 2006). There is also evidence that the fallopian tubes facilitate 
sperm storage to create a sperm reservoir and thus increase the likelihood of 
conception. It has been shown that human sperm bind by their heads to the tubal 
epithelial cells and preserve their viability (Lyons et al., 2006). The tubal 
secretions produced by peg cells are known to promote sperm capacitation, 
modify the affinity of human sperm for the oocyte (Munuce et al., 2009) and in 
addition provide nutrients and a favourable environment for the developing 
embryo (Buhi et al., 2000). A growing body of evidence suggests that tubal 
transport is not a passive process, but rather an active process that involves 
complicated interactions and can modulate fertilisation, embryo growth and 
differentiation. Considering this information, it is difficult to underestimate the 
importance of fallopian tubes in natural human conception. 
 
1.1.3. Endometrium 
The endometrium is the inner lining of the uterus that provides the optimal 
environment for embryo implantation once the developing embryo has reached 
the uterine cavity with the help from the fallopian tubes. The endometrium can 
roughly be divided into two regions: the basalis adjacent to the myometrium (the 
muscle layer of the uterus), and the functionalis that is situated between the 
endometrial surface epithelium and the basalis. The surface epithelium is formed 
from a single layer of columnar epithelial cells that rest on the endometrial 
stroma (connective tissue) containing endometrial glands and a rich supply of 
blood vessels. Throughout the menstrual cycle, the endometrium (especially the 
functionalis that is highly sensitive to hormonal fluctuations) undergoes the 
cycle of proliferation, secretion and degeneration as orchestrated by estrogen and 
progesterone produced by the ovaries. As already mentioned, in the proliferative 
phase estrogen stimulates cellular proliferation, whereas in the secretory phase 
progesterone promotes cellular differentiation, the endometrial glands reach their 
peak secretory activity and the endometrium becomes receptive to the 
implanting embryo. However, if implantation does not occur, the progesterone 
levels decrease and the endometrial lining is shed during menstruation.  
Stemming from tissue characteristics, the main function of the endometrium 
(or decidua during pregnancy) is to be receptive at the “right time”, have a 
successful dialogue with the implanting embryo (Altmäe et al., 2012) and 
provide a favouring environment and support throughout the pregnancy.  
As with all intricate mechanisms, a slightest disturbance can affect the 
functioning of the entire system and so is the case with the female reproductive 
system. In many women either the individual parts of the reproductive tract are 
dysfunctional or the cooperation between different parts is for some reason 
disrupted, resulting in a serious medical, emotional and socioeconomical 





Infertility is defined as the failure to achieve a successful pregnancy after one 
year or more of appropriate, timed unprotected intercourse (Practice Committee 
of American Society for Reproductive Medicine, 2013). Given that one in six 
couples is faced with some sort of infertility problems and the current prevalence 
of infertility among reproductive-aged women is approximately 10% [European 
Society of Human Reproduction and Embryology (ESHRE) 2014 fact sheet, 
http://www.eshre.eu/Guidelines-and-Legal/ART-fact-sheet.aspx], infertility can 
be considered a serious and widespread medical and socioeconomical problem. 
According to the “Women’s Health in Estonia” study conducted in 2004 (Part et 
al., 2007), 18% of women aged 18–44 reported having experienced periods of 
involuntary infertility (defined as difficulties in conceiving during one year of 
regular sexual intercourse). Although the epidemiology of infertility in Estonia is 
poorly studied, it is estimated that approximately 15–20,000 couples are 
infertile, which is especially worrisome, considering the current demographic 
trends (aging population and emigration). 
According to the ESHRE 2014 fact sheet, physiological causes in men and 
women both account for about one-third of infertility cases, whereas a problem 
in both partners is to be blamed in 25–40% of cases, and in 10–20% of infertility 
cases the cause remains unclear. Male infertility can mostly be attributed to 
suboptimal semen quality as seen on semen analysis (Cooper et al., 2010), while 
the causes for female infertility are more diverse and more difficult to diagnose. 
The major causes of female infertility are ovulatory disorders [premature ovarian 
insufficiency (POI), PCOS, age-related infertility], tubo-peritoneal infertility 
(TFI, endometriosis), and uterine abnormalities (anatomical malformations, 
fibroids). Unexplained infertility is diagnosed when current standard infertility 
evaluation methods (Cooper et al., 2010; Practice Committee of American 
Society for Reproductive Medicine, 2012) in both partners yield normal results. 
There are also regional differences in the causes of infertility worldwide. While 
damaged fallopian tubes due to an infection is the leading cause of infertility in 
developing countries (Audu et al., 2009), infertility caused by advanced maternal 
age and decreased ovarian function is an increasing problem in the western 
countries (Schmidt et al., 2012). Although the exact distribution of different 
causes of infertility in Estonia is unknown, a study conducted among infertility 
treatment clinic (the Nova Vita clinic in Viimsi, Estonia) patients in 2004–2005 
allows assuming that in Estonia, the leading cause of female infertility is TFI, 
followed by PCOS (Haller et al., 2006). 
 
1.2.1. Genetic component of human fertility and infertility 
The female reproductive lifespan is delineated by two events – menarche, the 
onset of first menstruation and attainment of reproductive capacity, and the 
menopause, the cessation of menstruations and the end of the normal 
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reproductive function. Both menarche and menopause are directly linked with 
the ovarian function and folliculogenesis. Although several environmental and 
lifestyle factors (nutrition, smoking) are known to modify the onset of both 
events, a considerable genetic background has also been identified (Stolk et al., 
2012; Carty et al., 2013; Fernandez-Rhodes et al., 2013; Perry et al., 2013; Perry 
et al., 2014), meaning that the female reproductive lifespan and ovarian-part of 
the fertility are to some extent determined by genetic factors. Furthermore, some 
candidate genes related to the hypothalamic-pituitary ovarian axis and 
folliculogenesis (FSHR, FST, INHBA, CGB/LHB gene cluster) have been 
directly associated with female fertility (measured by the number of children) 
(Kuningas et al., 2011). (Epi)genetically determined molecular processes are 
also known to influence functioning of the fallopian tubes (reviewed by Shaw et 
al., 2010) and the endometrium (Garrido-Gomez et al., 2013). The entire 
spectrum of genetic factors affecting the functioning of different parts of the 
female reproductive tract is currently unknown. 
Infertility as a condition is multifactorial in nature in the majority of cases, 
and thus multiple factors (lifestyle, environmental, physiological and genetic) 
can contribute to the condition. Over the years, great effort has been directed 
towards elucidating the molecular mechanisms behind the conditions causing 
female and male infertility and it has been concluded that, similarly to many 
other diseases, individual genetic variation is definitely one of the factors behind 
reduced fertility. While a few monogenic defects (for example in CFTR, 
PTPN11, SOX9) are known that lead to infertility (reviewed by Shah et al., 
2003), majority of infertility cases have a polygenic background and genetic 
variation (such as single nucleotide polymorphisms (SNPs) or tandem repeat 
sequences) in several genes contributes to the overall infertile phenotype. 
Diseases associated with infertility are believed to have a considerable 
heritability (Treloar et al., 1999; Vink et al., 2006), and as a result of extensive 
research, some genetic susceptibility factors have been discovered for most 
infertility-causing conditions, such as male infertility (Kosova et al., 2012), 
endometriosis (Rahmioglu et al., 2014), POI (Perry et al., 2013), PCOS 
(Goodarzi, 2007; Shi et al., 2012; Lee et al., 2015) and TFI (Morre et al., 2009b). 
The genetic component of the latter two conditions will be discussed in more 
detail in chapters 1.2.3. and 1.2.5. The genetic background of infertility-causing 
conditions has also been studied among Estonians, both in women (Altmäe et al., 
2010; Lamp et al., 2010; Saare et al., 2010; Lamp et al., 2011; Lamp et al., 2012) 
and in men (Saare et al., 2008; Lend et al., 2010; Peters et al., 2010). Owing to 
the above-mentioned studies, we know now significantly more about the genetic 




1.2.2. Tubal factor infertility 
TFI is characterised by partial or complete blockage of the fallopian tubes that 
interferes with the natural functions of the fallopian tubes – gamete 
transportation and fertilisation – and leads to decreased fertility. Difficulties in 
gamete transport may be attributed to scar tissue and adhesions in the region, or 
to functional damage to the ciliated cells in the fallopian tube epithelium. TFI 
accounts for approximately a third of all reported infertility cases (Miller et al., 
1999); however, in developing countries the prevalence of TFI can be as high as 
70% (Audu et al., 2009). The exact prevalence of TFI in Estonia is unknown, but 
according to the Estonian IVF Effectiveness and Cost report (Tonsiver et al., 
2013), TFI (diagnose code N97.1) is the main indication (46% of all National 
Health Insurance Fund covered treatment bills) for IVF treatment in Estonia.  
The main cause of TFI is pelvic inflammatory disease (PID), which can result 
in infertility in up to 60% of cases and the likelihood of developing TFI is 
greater after several episodes of PID (The ESHRE Capri Workshop Group, 
2002). PID is commonly caused by classic sexually transmitted pathogens, such 
as Neisseria gonorrhoeae and Chlamydia trachomatis, but recent studies have 
also linked Mycoplasma genitalium and bacterial vaginosis-associated anaerobic 
microorganisms with PID (reviewed by Mitchell and Prabhu, 2013). C. 
trachomatis is the causing agent of the most common bacterial sexually 
transmitted disease (STD), urogenital chlamydia (Adams et al., 2004; Torrone et 
al., 2014). The prevalence of genital chlamydia infection in Estonia is estimated 
to be approximately 5%, but among young (aged 18–35) females the prevalence 
is 7%, which is among the highest in Europe (Redmond et al., 2015). C. 
trachomatis is responsible for approximately half of TFI cases (reviewed by 
Debattista et al., 2003), but the exact prevalence of chlamydia-related TFI in 
Estonia is unknown.  
Tubal patency is usually evaluated using hysterosalpingography or laparo-
scopic surgery. However, it has been found that tubal blockages are strongly 
associated with the presence of anti-chlamydial antibodies in serum, and more 
specifically, anti-chlamydial IgG antibodies have been associated with TFI 
(Debattista et al., 2003). For this reason, serum C. trachomatis antibody testing 
is widely used to screen for tubal pathology and decide upon the need for 
subsequent laparoscopy during fertility work-up (den Hartog et al., 2006a). 
Serum C. trachomatis antibody testing is also commonly used in scientific 
research to determine the chlamydia-status in study subjects to distinguish 
potential chlamydia-related TFI.  
In females, C. trachomatis targets mainly the columnar epithelium of the 
cervix. Symptoms of genitourinary chlamydia infection in women include 
dysuria and abnormal vaginal discharge. Unfortunately, most C. trachomatis 
infections are asymptomatic or present with only mild symptoms, meaning that 
serious complications can occur silently before a woman even recognizes a 
problem. If left untreated on time, the infection can ascend to the upper genital 
tract (endometrium and fallopian tube epithelium) and cause PID. In addition to 
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PID and infertility, chlamydia infection in women increases the risk for chronic 
pelvic pain and ectopic pregnancy (Haggerty et al., 2010), that all result from 
damage and scarring of the fallopian tube tissue caused by proteases, clotting 
factors and tissue growth factors released from infected epithelial cells and 
inflammatory cells (Darville and Hiltke, 2010). 
While the consequences of genital chlamydia infection are thoroughly 
studied and recognized, the exact nature of the pathologic mechanisms leading 
to those consequences is unclear. Similarly to other infections, the nature of the 
host immune response and the interactions between the host and the pathogen 
determine the efficiency of infection clearance and occurrence of post-infection 
complications and pathological changes. It is hypothesised that the inflammatory 
damage caused by C. trachomatis can result from either too weak immune 
response (pathology due to chronic infection) or too strong immune response 
(pathology caused by hyperinflammation) (Debattista et al., 2003). Anti-
chlamydial immunity in the female reproductive tract is provided by elements of 
both the innate and acquired immunity. While the acquired immune system, 
consisting of humoral (antibody-mediated) and cell-mediated (mainly T-
lymphocytes) immunity, provides a more “tailored” immune response, the innate 
immune system responds first and provides a rapid and more general immune 
response. Elements of the innate host response include epithelial cells, host 
vaginal microbiota, antimicrobial peptides and pattern recognition receptors 
(PRRs), such as the Toll-like receptors (TLRs), components of the complement 
system and cells of the innate immune system (macrophages, neutrophils, 
natural killer cells) (den Hartog et al., 2006a; Horne et al., 2008; Hafner et al., 
2013). Since C. trachomatis is an intracellular pathogen, the epithelial cells 
targeted by the infection initiate the host response. Infected cells secrete 
chemokines, such as CCL5 (Sakthivel et al., 2008), that attract inflammatory 
leukocytes, and cytokines (such as IL-1) that further augment cellular 
inflammatory response, eventually leading to tissue damage (reviewed by 
Darville and Hiltke, 2010). The nature of anti-chlamydial immune response is 
determined by many factors: pathogen strain and viral load, presence of co-
infections, but also by hormones that fluctuate throughout the menstrual cycle 
(Hafner et al., 2013), and by individual genetic variability (Morre et al., 2009a). 
 
1.2.3. Genetics of tubal factor infertility 
The studies on the genetic susceptibility to TFI have entirely focused on 
chlamydia-related tubal damage and infertility. Data from twin studies allows 
estimating that host genetic factors contribute approximately 40% of the 
variation in immune response to C. trachomatis infection (Bailey et al., 2009). 
Since the susceptibility to C. trachomatis infection, the course and outcome of 
the infection depend on many factors, it is reasonable to believe that susceptibility 
to TFI is determined by many genes and the individual contribution of each gene 
and genetic variant is small. Majority of the studies have compared C. 
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trachomatis positive TFI patients with individuals with a different course (no 
tubal damage or TFI) of infection. Several studies using candidate gene 
approach have been carried out and all tested variants are located in genes that 
associate with host immune response and can roughly be divided into three 
major groups – cytokine signalling (IL-1B, IL-1RN, IL-6, IL-10, IL-12A, IL-12B, 
TGFB, TNF-α, IFNG), antigen presentation (HLA, MICA) and PRRs (TLR2, 
TLR4, TLR9, CD14, CARD15/NOD2, MBL2) (Cohen et al., 2000; Kinnunen et 
al., 2002; Cohen et al., 2003; Morre et al., 2003; Murillo et al., 2003; den Hartog 
et al., 2006b; Sziller et al., 2007b; Karimi et al., 2009; Mei et al., 2009; Ohman 
et al., 2009; Ouburg et al., 2009; Ohman et al., 2012). Only a few markers have 
been tested in more than one study, and thus it is difficult to draw any firm 
conclusions. As far as cytokine signalling and antigen presentation are 
concerned, an increased risk of developing TFI after genital chlamydia infection 
has been associated with certain HLA alleles (Kinnunen et al., 2002) and with 
genetic variation in IL-10 and TNF-α (Ohman et al., 2009), and IL-12B (Ohman 
et al., 2012). Findings related to PRRs are discussed in the following paragraphs. 
 
1.2.3.1. Toll-like receptors 
TLRs represent the most studied PRRs in the context of TFI. TLRs are 
expressed on macrophages, dendritic and epithelial cells, and recognize specific 
pathogen-associated molecular patterns (also known as PAMPs), such as 
bacterial cell surface components. Activation of TLRs consecutively results in 
recruitment of phagocytic cells and the production of pro-inflammatory 
cytokines and chemokines. Genetic variation in the form of SNPs has been 
described in several TLRs, but the most studied are the two cosegregating SNPs 
Asp299Gly (rs4986790) and Thr399Ile (rs4986791) in TLR4 (9q33.1), and 
Arg753Gln (rs5743708) in TLR2 (4q32), which affect PAMP-receptor binding 
and have been associated with susceptibility to several infections (reviewed by 
Schroder and Schumann, 2005). It has been shown that TLR2, TLR4 and TLR9 
are among the main TLRs that are involved in the immune response toward C. 
trachomatis (reviewed by Joyee and Yang, 2008). Thus, SNPs in these three 
TLRs have been studied in relation to C. trachomatis infection and tubal damage 
(Morre et al., 2003; den Hartog et al., 2006b; Karimi et al., 2009; Ouburg et al., 
2009). Apart from a protective effect regarding development of tubal pathology 
reported for one specific haplotype in TLR2 (Karimi et al., 2009), no significant 
associations have been found.  
 
 
1.2.3.2. Mannose-binding lectin 
Mannose binding lectin (MBL) is a secreted PRR that binds a wide variety of 
pathogens and is an important part of the complement system, thus providing the 
first-line defence against invading pathogens, including C. trachomatis 
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(Swanson et al., 1998). In addition to mediating complement system activation, 
MBL also modulates inflammation and apoptotic cell clearance (Dommett et al., 
2006). MBL is encoded by the MBL2 gene (10q11.2), and more than 400 SNPs 
have been described in the gene region. Most studied are the six common 
polymorphisms −550 H/L (rs11003125) and −221 X/Y (rs7096206) in the 
promoter region, +4 P/Q (rs7095891) in the non-translated region, and three 
polymorphisms located in exon 1 at codon 52 A/D (rs5030737), codon 54 A/B 
(rs1800450) and codon 57 A/C (rs1800451) (Madsen et al., 1995; Madsen et al., 
1998). However, the latter is very rare in European populations (Dommett et al., 
2006). These six SNPs also have an effect on serum MBL levels (Lipscombe et 
al., 1992; Madsen et al., 1994; Naito et al., 1999). Given the important role of 
MBL in immune system regulation, genetically determined variation in MBL 
concentration has been associated with the susceptibility and course of different 
infections (reviewed by Eisen and Minchinton, 2003) and fertility-related 
conditions (van de Geijn et al., 2007a; Christiansen et al., 2009). Genetic 
variation in MBL, particularly codon 54 A/B (rs1800450), has been associated 
with an increased risk of developing TFI after genital chlamydia infection 
(Sziller et al., 2007b). The importance of other MBL2 SNPs in TFI has not been 
studied. 
 
1.2.3.3. Chemokine receptor CCR5 
Chemokine receptor CCR5 is generally not considered as a PRR, but it is a 
transmembrane receptor expressed on several cells of the innate and adaptive 
immune system, such as monocytes, dendritic cells, T helper 1 cells and 
macrophages. CCR5 binds proinflammatory chemokines (i.e. CCL5, MIP-1α 
and MIP-1β) produced by activated immune cells and thus the primary role of 
CCR5 is to facilitate immune cell cross-talk. However, CCR5 can also act as a 
PRR (Floto et al., 2006). C. trachomatis infection up-regulates production of the 
chemokine CCL5, a ligand for CCR5 in epithelial cells (Maxion and Kelly, 
2002) and T cells expressing CCR5 dominate in inflammatory disease and 
mucosal surfaces (Sallusto et al., 1998). The CCR5 is encoded by the CCR5 
gene (3p21.31), and the gene region includes over 400 SNPs. In addition, a 
functional 32-bp deletion has been described in CCR5 (CCR5delta32), which 
results in premature termination of the protein (Mueller and Strange, 2004). As a 
consequence, individuals homozygous for this deletion do not express CCR5 on 
the cell surface, while heterozygous individuals have a reduced number of CCR5 
receptors (Liu et al., 1996). The CCR5delta32 is mainly known for its ability to 
hinder HIV-1 transmission (Paxton and Kang, 1998). So far, only two studies 
have investigated the role of CCR5delta32 in TFI, and while Barr and colleagues 
(Barr et al., 2005) reported a protective effect regarding development of tubal 
pathology for CCR5delta32, no such effect was seen in a later study (Mania-
Pramanik et al., 2011).  
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1.2.4. Polycystic ovary syndrome  
PCOS is a common endocrine disorder among reproductive-aged women, with 
an estimated prevalence of approximately 10% (but it can be as high as 20%, 
depending on the diagnostic criteria used) (Sirmans and Pate, 2013). The exact 
epidemiology of PCOS in Estonia is unknown, but the prevalence is estimated to 
be relatively similar worldwide. The clinical presentation in patients varies 
considerably, but symptoms include menstrual cycle disturbances, hyper-
androgenism (presenting as hirsutism, acne, and alopecia), polycystic ovarian 
morphology, obesity and insulin resistance. The syndrome is often accompanied 
by infertility, which affects approximately 40% of women with PCOS, and 
moreover, PCOS is the most common cause of anovulatory infertility (Teede et 
al., 2010).  
Due to heterogeneous clinical manifestation, diagnosis of PCOS cannot be 
made based on a single criterion. Currently, there are three sets of proposed 
criteria for diagnosing PCOS. The NIH/NICHD criteria include clinical and/or 
biochemical hyperandrogenism and menstrual dysfunction. Diagnosis according 
to the so-called Rotterdam criteria is made when two of the following 
characteristics are present: clinical and/or biochemical hyperandrogenism, oligo- 
or anovulation, and polycystic ovaries (presence of eight or more follicles <10 
mm in diameter and/or increased ovarian stroma) (The Rotterdam ESHRE 
ASRM-Sponsored PCOS Consensus Workshop Group, 2004). Finally, the 
criteria of the Androgen Excess Society include clinical and/or biochemical 
hyperandrogenism, and ovarian dysfunction and/or polycystic ovaries (Azziz et 
al., 2006). All three also state that other androgen excess or related disorders 
(thyroid disease, hyperprolactinemia, nonclassic congenital adrenal hyperplasia) 
have to be excluded. Currently, experts suggest using the Rotterdam criteria for 
diagnosing PCOS (Legro et al., 2013). 
Clinical or biochemical androgen excess is a central feature in all proposed 
diagnostic criteria, underlining its important role in the disease pathogenesis, 
although signs of androgen excess are not always present (reviewed by Goodarzi 
et al., 2011). The three main cornerstones of the disease – hyperandrogenism, 
ovarian dysfunction and hyperinsulinism resulting from insulin resistance 
interact in a loop system to produce the clinical picture characteristic to PCOS 








Hyperinsulinism observed in PCOS women is probably caused by both 
increased basal insulin secretion and decreased insulin clearance (insulin 
resistance) (Dunaif, 1997). Furthermore, hyperandrogenism contributes to insulin 
resistance and hyperinsulinemia in turn augments androgen production, resulting 
in a vicious circle (Dunaif, 1997). The androgen excess characteristic to PCOS is 
mainly of ovarian origin stemming from a steroidogenic defect in theca cells that 
is further augmented by increased LH and insulin levels (reviewed by Diamanti-
Kandarakis, 2008). The intra-ovarian hyperandrogenism most likely promotes 
early follicular growth, which leads to a 2–5 mm follicle excess, and together 
with hyperinsulinism/insulin resistance, results in disturbed follicle selection 
process, follicular arrest and polycystic ovarian morphology (Jonard and 
Dewailly, 2004). The disturbances in folliculogenesis are also to blame for the 
anovulation and resulting subfertility. 
The exact mechanisms leading to development of PCOS are in large part 
unknown, but it is clear that environmental factors, especially lifestyle and 
weight, have a huge impact on how severely the disease is manifested (Goodarzi 
et al., 2011). There is also growing evidence that genetic variants and 
epigenetics contribute to the dysregulation behind PCOS symptoms, providing 





1.2.5. Genetics of polycystic ovary syndrome 
There is strong evidence to suggest that susceptibility to PCOS is determined by 
genetic factors. For example, according to a twin-study, the heritability of PCOS 
can be as high as 70% (Vink et al., 2006). At the same time, it has become 
evident that complex interactions between genetic and environmental factors are 
not completely understood (reviewed by Crosignani and Nicolosi, 2001), which 
together with the broad spectrum of PCOS manifestation hinders the detection of 
genetic susceptibility loci. However, it is clear that PCOS is a complex genetic 
trait, meaning that many different genes contribute to the etiopathogenesis of the 
disease. Similar to other complex traits, majority of studies have used a 
candidate gene approach and more than 70 candidate genes have been tested for 
association with PCOS in different populations, unfortunately with inconsistent 
results (reviewed by Urbanek, 2007; Barber and Franks, 2010). Candidate genes 
have been selected based on the main characteristics of the PCOS syndrome, 
such as hyperandrogenism, obesity and insulin resistance, disturbed 
folliculogenesis, therefore the tested genetic variants have mainly been chosen 
from pathways related to androgen production and action (AR, BMP15, the CYP 
family, GDF9, STAR, etc.), insulin action (INS, INSR, IGF1, IGF2, IGF1R, 
LEPR, etc.), and gonadotropin secretion (FSHB, FSHR, FST, GNRHR, INHA, 
LHB, SHBG, etc.) (Goodarzi, 2007; Urbanek, 2007; Barber and Franks, 2010). 
The tandem repeats in the androgen receptor gene (AR) and insulin gene (INS) 
are two of the most studied genetic variants and their association with PCOS will 
also be discussed below. 
During the last couple of years, researchers have also performed genome-
wide association studies (GWAS) to use a hypotheses-free approach for finding 
disease associations, and have found susceptibility loci on chromosomes 2, 8, 9, 
11, 12, 16, 19 and 20 (Chen et al., 2011; Shi et al., 2012; Lee et al., 2015). Genes 
within or near these loci include DENND1A, KHDRBS3, FSHR, HMGA2, INSR, 
LHCGR, RAB5B, SUOX, SUMO1P1, THADA, TOX3, YAP1. Although these loci 
were first identified in PCOS patients of Asian origin, later meta-analyses 
observed largely similar results among Europeans (Louwers et al., 2013; Brower 
et al., 2015), suggesting patients with different ethnic backgrounds share 
common pathogenic mechanisms. Whether an independent GWAS among 
Europeans confirms these results or unravels additional novel susceptibility loci 
remains to be seen in the nearest future. 
 
1.2.5.1. Androgen receptor gene 
All androgens manifest their actions through the androgen receptor (AR). The 
AR is a nuclear transcription factor and thus the binding of androgens to AR 
regulates the expression of a wide variety of genes, several of which are 
expressed during folliculogenesis in the developing follicle. The gene encoding 
the receptor (AR) is located at Xq11-12 and contains 8 exons (Lubahn et al., 
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1988). The N-terminal transcription activation domain in encoded by exon 1, 
which also contains a highly polymorphic CAG repeat that results in a 
polyglutamine stretch on translation and is commonly referred to as the AR CAG 
microsatellite. The number of CAG repeats ranges from ~10 to ~30 in the 
general population, and the most common alleles among Scandinavians contain 
approximately 20 repeats (Lund et al., 2000). It has been shown that the length 
of the CAG repeat correlates inversely with the transactivation function of the 
AR, at least in vitro (Chamberlain et al., 1994). Thus, several authors have tried 
to find associations between AR CAG microsatellite length and various 
pathogenic conditions. Very long repeats (>40) have been associated with 
androgen insensitivity and related conditions, whereas shorter AR CAG tracts 
have been linked with increased androgen sensitivity and concomitant increased 
risk for prostate cancer (reviewed by Kumar et al., 2011). Since increased 
androgen action is also characteristic to PCOS, numerous studies have assessed 
the AR CAG microsatellite length in PCOS patients of different ethnic origin, 
and while some authors have found associations with shorter AR CAG repeats 
(Shah et al., 2008; Van Nieuwerburgh et al., 2008; Xita et al., 2008; Schuring et 
al., 2012; Xia et al., 2012), others have not (Mifsud et al., 2000; Jaaskelainen et 
al., 2005; Ferk et al., 2008b; Kim et al., 2008; Echiburu et al., 2012; Skrgatic et 
al., 2012; Rajender et al., 2013), and one study even found that longer AR CAG 
microsatellites are more prevalent among PCOS patients (Hickey et al., 2002). 
Recently published systematic reviews and meta-analyses conclude that the AR 
CAG microsatellite is most likely not a susceptibility factor for PCOS (Wang et 
al., 2012; Rajender et al., 2013; Zhang et al., 2013), but may contribute to the 
hyperandrogenemic aspect of the disease (Zhang et al., 2013; Peng et al., 2014). 
One factor that could help to explain these inconsistent results is the 
phenomenon of X-chromosome inactivation (XCI). Since women have two 
copies of the X-chromosome, one of them has to be inactivated in all somatic 
cells. The XCI is random in roughly half of the women, but skewed inactivation 
patterns can be seen in the other half, and these women have the same X-
chromosome inactivated in >60 % of somatic cells (Naumova et al., 1996). Such 
skewed inactivation can affect the activity of AR (and other X-linked genes), and 
ideally, the epigenetic effect of XCI should be taken into account in association 
studies. Indeed, some studies have proposed that alterations in XCI pattern may 
be associated with PCOS (Hickey et al., 2002; Hickey et al., 2006; Shah et al., 
2008; Dasgupta et al., 2010; Schuring et al., 2012), but the results are 
inconclusive. 
 
1.2.5.2. Insulin gene 
Insulin is mostly known for mediating glucose uptake in muscle and adipose 
tissue; however, insulin can also serve as a para- or autocrine regulator of gene 
transcription, and cell growth and differentiation, including steroidogenesis in 
the ovaries (Franks et al., 1999). The insulin gene (INS, 11p15.5) includes 3 
28 
exons and there are more than 200 SNPs in the gene region. The 5’ region of the 
INS gene also includes a minisatellite (VNTR – variable number of tandem 
repeats), which is in linkage disequilibrium (LD) with other SNPs in the area 
(Bennett et al., 1995). The INS VNTR is polymorphic due to the ranging number 
of a certain 14–15 bp tandem repeat and the VNTR alleles are divided to 3 
classes, based on the number of tandem repeats: class I alleles (30–60 repeats), 
class II alleles (60–120 repeats), class III alleles (120–170 repeats); however, 
class II alleles are very rare among Europeans. The length of the INS VNTR 
affects insulin transcription, such that longer (class III) VNTR alleles correlate 
with greater transcriptional activity in vitro (Kennedy et al., 1995); however, in 
the pancreas, the class I (shorter) alleles are associated with greater 
transcriptional activity (reviewed by Pugliese and Miceli, 2002). Moreover, 
there is evidence the INS VNTR may also affect the expression of the 
neighbouring insulin-like growth factor II gene (IGF2) (Paquette et al., 1998). 
 Because of the central role of insulin action in PCOS, the INS VNTR has 
also been studied in the context of PCOS, but similar to AR CAG, with 
inconsistent results (Waterworth et al., 1997; Vankova et al., 2002; Ferk et al., 
2008a; Xu et al., 2009; Yun et al., 2012; Skrgatic et al., 2013). Even meta-
analyses conducted on this matter or studies including multiple data sets have 
yielded different results both in favour (Yan et al., 2014) and against (Powell et 
al., 2005; Song et al., 2014) an association. 
 
 
1.3. Treatment of infertility 
Due to the diverse nature of conditions behind infertility, a variety of treatment 
options are used to tackle the problem – hormonal medications, surgical 
treatment, intrauterine insemination, and in more difficult cases assisted re-
productive technologies. 
Hormonal treatment is the first choice in cases where female infertility due to 
ovarian dysfunction is diagnosed. Ovarian stimulation drugs (such as 
Clomiphene, Tamoxifen) can be prescribed to women with ovulatory problems, 
while some women with PCOS may benefit from treatment with drugs 
(Metformin) that alleviate insulin resistance (Legro et al., 2013). Surgical 
treatment is used in cases where removal of adhesions is indicated – such as TFI 
or endometriosis. Surgery is also used to remove endometriosis-associated 
endometrial lesions from the abdominal cavity (Practice Committee of the 
American Society for Reproductive Medicine, 2012) and remove ovarian cysts 
typical to PCOS. Quite often, hormonal treatment is used together with surgical 
intervention (especially in endometriosis and PCOS). 
Intrauterine insemination (IUI), whereby sperm is introduced directly to the 
uterus using a special catheter, is a relatively non-invasive, safe and cost-
effective treatment option, but unblocked fallopian tubes and normal ovulation 
are a prerequisite for the procedure. 
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However, if the aforementioned treatments fail or in more complex cases of 
infertility, assisted reproductive technologies (ART) are used. 
 
1.3.1. Assisted reproductive technologies and  
controlled ovarian stimulation 
ART include all treatments or procedures that include the in vitro handling of 
human oocytes and sperm, or embryos, for the purpose of establishing a 
pregnancy (Zegers-Hochschild et al., 2009). This also includes IVF and 
intracytoplasmic sperm injection (ICSI). IVF alone or in combination with ICSI 
is the most used procedure for infertility treatment and can help to overcome 
both female and male factor infertility. In 2011, nearly 600,000 ART treatment 
cycles were reported from 33 European countries and more than 5 million IVF 
babies have been born worldwide since the birth of the first IVF baby in 1978 
(ESHRE 2014 ART fact sheet). According to the National Institute for Health 
Development health statistics, today approximately 2–3% of all babies born in 
Estonia are IVF babies. 
IVF treatment includes three stages: a) controlled ovarian stimulation (COS), 
b) in vitro fertilisation of the obtained oocytes and incubation of the embryos, 
and c) embryo transfer into the uterus (Figure 4). Any good quality embryos not 




Figure 4. Schematic overview of the IVF treatment process. Exogenous FSH together 
with the GnRH agonist or antagonist protocol is used to stimulate the growth and 
maturation of multiple follicles. Oocytes are retrieved on ovarian puncture and then 
fertilised in vitro. After incubation, good quality embryos are transferred to the uterus. 
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One of the main goals of IVF treatment is to obtain multiple oocytes with good 
quality that could then be fertilised, making COS a key step in IVF treatment. 
During COS, multiple ovarian follicles are induced to grow and mature by 
stimulating the ovaries with exogenous FSH together with either the GnRH 
agonist or antagonist protocol. Final follicular maturation is achieved using 
exogenous human chorionic gonadotropin (hCG), which is followed by oocyte 
retrieval on vaginal ultrasound-guided ovarian puncture (OPU). The ovarian 
response to exogenous hormonal stimulation varies greatly among individuals, 
and unfortunately, in some women may result in suboptimal numbers of 
retrieved oocytes (poor responders), while in others the standard amount of 
hormones administered is too much and they develop a serious complication – 
the ovarian hyperstimulation syndrome (OHSS). In 2011, 0.6% of all treatment 
cycles in Europe resulted in OHSS (ESHRE ART 2014 fact sheet). Over the 
years, COS protocols have undergone various changes and doctors and scientists 
worldwide are constantly looking for ways to improve the protocols and make 
them safer and more effective. Today, the optimal clinical management of IVF-
COS includes a) the prospective identification of the ovarian reserve, b) the 
individualisation of the COS treatment protocol, and c) the prevention of 
potential complications (Arslan et al., 2005).  
The oocytes obtained during COS are then fertilised in vitro with motile 
spermatozoa (traditional IVF), or a single selected sperm is injected directly into 
the oocyte (ICSI). ICSI is the recommended choice of treatment in couples with 
male factor infertility or with unexplained treatment failure in previous IVF 
cycle, but also in certain cases of female infertility. According to the ESHRE 
2014 ART fact sheet, ICSI is the most common treatment technique that 
accounts for two-thirds of all treatments worldwide, and both IVF and ICSI yield 
a pregnancy rate of ~30% per embryo transfer. The proportion of used treatment 
techniques (IVF or ICSI) is similar in Estonia (Tonsiver et al., 2013). 
Fertilised oocytes are then incubated and routinely assessed 16-18h after 
insemination, and the day after to evaluate the embryo cleavage of normally 
fertilised oocytes. Morphology of cleavage stage embryos is one of the markers 
used to assess the quality of the embryos, and different scoring systems have 
been developed (reviewed by Machtinger and Racowsky, 2013). If the embryos 
are developing normally, generally 1–2 embryos are transferred to the uterus 2-3 
days after fertilisation (4–8 cell stage) or 5 days after fertilisation (blastocyst 
stage).  
Despite advancements in IVF technologies, the success rate per IVF treatment 
cycle remains around 30% even if embryos with a seemingly excellent quality 
are transferred. Currently, systemic oxidative stress (Ahelik et al., 2015) and 
overweight (Lapp, 2013), but also female age, duration of subfertility, basal FSH 
levels and the number of oocytes obtained on COS (all indicative of the ovarian 
function) are considered somewhat predictive of pregnancy following treatment 
with IVF/ICSI (van Loendersloot et al., 2010). Markers prognostic of treatment 
success are extensively sought for and novel methods have been proposed for 
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timing embryo transfer to match endometrial receptivity (Ruiz-Alonso et al., 
2013) and for assessing embryo quality (Rodrigo et al., 2014). Although the 
importance of endometrial receptivity and embryo-endometrial cross-talk has 
recently been underlined, the success of the first stage of IVF treatment – the 
ovarian stimulation stage – remains the main modifier of treatment efficiency 
and reliable markers targeting this treatment stage could substantially improve 
the overall treatment outcome.  
 
1.3.2. Markers of ovarian function in natural and  
assisted conception 
Because the ovarian reserve and the ovarian function are the key limiting factors 
in achieving pregnancy both in natural and assisted conception, various ovarian 
reserve tests are used to a) predict the ovarian reserve and reproductive potential, 
and b) predict the ovarian response and outcome of IVF-COS (reviewed by 
Jirge, 2011). In short, the most used ovarian reserve tests consider woman’s age, 
hormone levels (basal FSH, AMH, etc.) and ultrasound parameters (antral 
follicle count, ovarian volume and blood flow) either separately or in various 
combinations. As with other markers in clinical practice, an ideal marker for 
ovarian function should be easily measurable and inexpensive, minimally 
invasive and maximally informative, and most importantly, minimally affected 
by other factors. All currently used ovarian reserve markers have their pros and 
cons, but together with the personalised medicine revolution and because the 
ovarian function is directly related to reproductive aging, which has a 
considerable heritable component (as high as 90%) (de Bruin et al., 2001), a lot 
of research has been directed on finding the genetic predictors of reproductive 
aging and ovarian function. By definition, a genomic/genetic biomarker is a 
DNA or RNA characteristic indicative of normal biologic, or on the contrary 
pathogenic, processes, and/or response to therapeutic or other intervention 
(Novelli et al., 2008). DNA characteristics that could be considered as 
biomarkers include SNPs, tandem repeat sequences, DNA modifications (such 
as methylation), insertions, deletions and copy number variations (Novelli et al., 
2008). The diagnostic value of genomic biomarkers lies in their robustness and 
in theory they could be used for screening, diagnosing and monitoring the 
activity of a disease, but also for personalising treatment regimens and assessing 
therapeutic responses (Novelli et al., 2008). 
These markers are believed to also complement the existing methods used for 
monitoring the ovarian reserve and function (ultrasound, hormone 
measurements), mainly because genetic markers are stable, reliable, and could 
also provide some information about the reproductive potential of the ovarian 
reserve. Therefore, such markers could be of use in clinical ovarian reserve and 
function assessment in natural and assisted conception, where reliable genetic 
markers are extensively sought for in order to develop a pharmacogenetic 
approach for IVF-COS and thereby increase treatment effectiveness and reduce 
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harmful side effects (reviewed by Altmäe et al., 2011; Lledo et al., 2014). 
Although several markers with a clinical potential (FMR1, FSHR) have been 
proposed (Gleicher et al., 2009a; Gleicher et al., 2009b; Yan et al., 2013), 
genetic markers of ovarian reserve/IVF-COS are currently not used in clinical 
practice. 
Until recently, the search for genetic predictors of ovarian reserve/IVF-COS 
focused on obvious candidates (FSHR) and certain pathways (estrogen 
synthesis/metabolism, AMH signalling), meaning that the overall number of 
tested variants was small. Advancements in genotyping technologies and the 
formation of large international consortiums have enabled scientists to use a 
genome-wide hypotheses-free approach in the search for genetic markers of 
reproductive aging and the ovarian reserve (He et al., 2009; Schuh-Huerta et al., 
2012a; Stolk et al., 2012; Carty et al., 2013). These studies have identified 
several loci that show strong associations with studied traits (UIMC1, SYCP2L, 
MCM8 and age at menopause; MYADML and FSH levels); however, these 
variants explain only a small proportion of the phenotypic variation, and in most 
part their functional significance is unclear. Unfortunately the GWAS-approach 
has been unsuccessful for identifying genetic predictors for IVF success or IVF-
COS (van Disseldorp et al., 2011), probably because a genome-wide approach 
needs very large and rather homogenous study cohorts that are difficult to 
achieve in IVF setting and the stringent analysis criteria dismiss the variants 
with smaller effect sizes. However, the reproductive aging and the ovarian 
function most likely share some of the genetic background (Rosen et al., 2010), 
as also shown by a study that successfully associated menopause-related variants 
with ovarian reserve markers (Schuh-Huerta et al., 2012b). In this study, 
rs16991615 (MCM8) which has been associated with menopausal age in 
Caucasian women (He et al., 2009; Stolk et al., 2012) was associated with the 
number of antral follicles (Schuh-Huerta et al., 2012b). This demonstrates that 
the genetic variants associated with reproductive aging are good candidates for 
markers of ovarian function and IVF-COS. 
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2. AIMS OF THE STUDY 
The general objective of the current study was to assess the importance of 
various genetic factors in the etiology of female infertility and especially in 
those conditions affecting the function of the ovary and the fallopian tubes. In 
addition, several genetic variants that could be related to the ovarian reserve, 
controlled ovarian stimulation and in vitro fertilisation treatment outcome 
parameters were evaluated. 
 
Accordingly, the specific aims were: 
1. To assess whether genetic variation in insulin and androgen receptor genes is 
associated with PCOS. 
2. Determine the prevalence of chlamydia-induced TFI among Estonian TFI 
patients. 
3. To analyse polymorphisms in genes modulating immune response to assess 
whether they affect susceptibility to TFI. 
4. To evaluate if genetic variants related to ovarian aging are associated with 
ovarian function, COS and IVF treatment parameters. 
5. To consider the suitability of these genetic variants for use as markers of 
ovarian function, COS and IVF treatment. 
9
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3. MATERIALS AND METHODS 
All the studies included in this thesis have been approved by the Research Ethics 
Committee of the University of Tartu, and an informed consent has been 
obtained from all participants. Studies are summarised in Table 1. 
 
 
3.1. Study subjects, clinical data and IVF 
IVF patients  
All patients undergoing IVF or ICSI at the Nova Vita Clinic (Estonia) from 2004 
to 2007 were recruited in the study. All included women had been suffering 
from primary or secondary infertility for at least one year. The reason for 
infertility was diagnosed as follows: 
• PCOS 
PCOS was diagnosed based on the criteria established by the Rotterdam PCOS 
consensus group (The Rotterdam ESHRE ASRM-Sponsored PCOS Consensus 
Workshop Group, 2004): oligo- or anovulation; clinical or biochemical 
hyperandrogenism and/or polycystic ovaries. The presence of two out of the 
three aforementioned criteria was necessary for diagnosing PCOS.  
• TFI 
Either hysterosalpingography or diagnostic laparoscopy was used for diagnosing 
tubal occlusions. The main findings on laparoscopy were unspecified blockage 
and/or surgery of fallopian tubes, sacto- or hydrosalpinx, adhesions, and abscess, 
all characteristic to a previous episode of PID, which was therefore considered to 
be the main cause for TFI. 
• Endometriosis 
The presence of endometriotic lesions characteristic to the disease was 
confirmed by diagnostic laparoscopy, as suggested by the American Society for 
Reproductive Medicine (Practice Committee of the American Society for 
Reproductive Medicine, 2012). 
• Male factor infertility 
Male factor infertility was diagnosed when the female counterpart was lacking 
any obvious reason for infertility, while decreased semen quality as diagnosed 
by World Health Organization criteria was present in the male. 
• Other 
Other causes for infertility included endometrial hyperplasia, uterine myoma, 
ovulatory dysfunction, and unexplained infertility, which was considered to be 
present when the woman was lacking all of the abovementioned reasons for 
infertility and the male semen quality was normal, but the couple had 
nevertheless experienced infertility for more than a year.  
From this dataset including 439 women, smaller subsets were selected for 
individual studies depending on study objectives as shown in Table 1 and on 




Figure 5. Schematic representation of patient overlap between different studies. 
 
 
Figure 6. Distribution of diagnoses for infertility in study cohort. 
 
 
Women with ectopic pregnancy  
Study IV also included women with previous ectopic pregnancy (n=178, age 
39.3±5.2 years), who represented women with tubal damage but without 
infertility. DNA and serum samples, as well as medical history for this group 
were obtained from the Estonian Genome Center of University of Tartu.  
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Controls 
Two hundred women (age 39.8±5.3 years) with proven fertility (i.e. at least 2 
children) and 200 women (age 45.7±18.1 years) representing the general 
population were enrolled in Studies III and IV as controls. Control group DNA 
and serum samples together with medical history were also obtained from the 
Estonian Genome Center of University of Tartu.  
 
Clinical data 
Metabolic assays (Studies I & II) 
Serum samples for measuring metabolic parameters were collected during the 
first five days of a spontaneous menstrual cycle. Serum levels of fasting insulin 
as well as glucose were measured by chemiluminescence immunoassay 
(Immulite 2000; Siemens Healthcare Diagnostics, Deerfield, IL, USA) and 
glucose oxidase method (Cobas Integra 800®, Mannheim, Germany), 
respectively. The homeostasis model assessment index ratio for insulin 
resistance (HOMA-R index) was also calculated (Vrbikova et al., 2002). 
 
History of sexually transmitted diseases and Chlamydia trachomatis-specific 
IgG antibodies (Studies III & IV) 
Any information regarding previous episodes of genital infections associated 
with Chlamydia trachomatis was collected from patient medical records. In 
addition, patient serum samples were tested for presence of C. trachomatis-
specific IgG antibodies by ELISA (EUROIMMUN, Medizinische Labor-
diagnostika AG, Germany). Patients with a positive antibody analysis or a past 
infection in anamnesis were considered positive for C. trachomatis. The serum 
samples of women with ectopic pregnancy and control group women used in 
Study III and IV were also tested for presence of C. trachomatis-specific IgG 
antibodies by ELISA (EUROIMMUN). 
 
Early follicular phase parameters (Studies I, II & V) 
Transvaginal ultrasound to assess ovarian volume and early follicle count were 
performed during a spontaneous menstrual cycle. Ovarian volume, measured by 
ultrasound, was estimated according to the following formula: 1/2(A × B × C), 
where A is the longitudinal diameter, B is the anteroposterior diameter and C is 
the transverse diameter of the ovary. The number of small antral follicles was 
estimated by transvaginal ultrasound scanning of each ovary in longitudinal 
cross-section. Mean follicle number and mean ovarian volume were calculated 
as the sum of the left and right ovaries divided by two. 
 
Serum samples for measuring hormonal levels were collected during the first 
five days of a spontaneous menstrual cycle. Levels of FSH, LH, estradiol, 
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testosterone and dehydroepiandrosterone sulphate (DHEAS) were measured 
using chemiluminescence immunoassay (Immulite 2000; Siemens Healthcare 
Diagnostics, Deerfield, IL, USA).  
 
COS parameters (Study V) 
Patients undergoing IVF as well as ICSI were included in the study. COS was 
conducted according to the GnRH antagonist (Cetrotide, Merck Serono, Geneva, 
Switzerland) or agonist (Cetrotide) protocol with the administration of 
recombinant FSH (rFSH) (Gonal-F, Merck Serono, or Puregon, Schering-
Plough, Kenilworth, USA) for 9–10 days until 1 day before hCG (Ovitrelle, 
Merck Serono) administration. The COS follow-up included 3–4 ultrasound 
assessments of endometrial and follicular growth. Daily GnRH antagonist 
administration (0.25mg, Cetrotide) was initiated if at least one follicle reached 
the size of ≥14 mm. The GnRH antagonists were given for 4–5 days up to and 
including the day of hCG administration. Final follicular maturation was 
achieved using 250 μg of hCG, followed by ovarian puncture (OPU) 36 h later. 
The ovarian stimulation parameters analysed in Study V included: a) total 
amount of rFSH used (IU); b) amount of FSH administered per retrieved oocyte 
(IU/oocyte); c) number of ovarian follicles punctured (OPU follicles) and d) 
number of oocytes retrieved at puncture. 
 
IVF treatment parameters (Studies IV & V) 
Patients undergoing frozen embryo transfer were excluded from the study. A 
maximum of three 2-day embryos were transferred into the uterus, with vaginal 
progesterone (Lugesteron, Leiras, Turku, Finland) used for luteal support. 
Biochemical pregnancy was confirmed with a positive serum hCG test 
performed 14 days after embryo transfer, whereas clinical pregnancy was 
defined as the presence of gestational sac(s) with fetal heartbeat on transvaginal 
sonography 6–7 weeks of gestation. The IVF treatment parameters analysed in 
Study V included: a) biochemical pregnancy and b) clinical pregnancy. 
 
 
3.2. Genotyping of polymorphisms 
Different genotyping methods were used to analyse 47 polymorphic loci 
(tandem repeats, deletions and SNPs) in 24 different genomic regions (Table 1). 
In addition, for the AR gene located on the X-chromosome, the XCI pattern was 
also determined. 
Genomic DNA was extracted from peripheral EDTA blood using the salting-
out method (Aljanabi and Martinez, 1997). Before genotyping, polymerase chain 
reaction (PCR) was performed. Loci of interest were amplified individually, 
except when SNaPshot Multiplex primer extension (duplex PCR) or Sequenom 
MassArray iPLEX assay (multiplex PCR) were used. 
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3.2.1. Tandem repeat analysis (Studies I & II) 
Tandem repeats are stretches of DNA where a pattern of one or more nucleotides 
is repeated and the repetitions are directly adjacent to each other. Tandem 
repeats are further classified as microsatellites (<10 repeating nucleotides, also 
known as short tandem repeats) or minisatellites (10–60 repeating nucleotides). 
When the number of repeating nucleotides in a minisatellite is variable, the term 
variable number of tandem repeat (VNTR) can also be used. In our study, two 
tandem repeats were analysed: INS VNTR and AR CAG microsatellite together 
with the XCI pattern. 
The INS VNTR was genotyped using the surrogate marker –23 HphI A/T 
(Lucassen et al., 1993), which was genotyped using PCR combined with 
restriction fragment length polymorphism (PCR-RFLP) analysis.  
The number of CAG repeats in the AR CAG microsatellite was determined 
by electrophoresis of fluorescently labelled PCR products. The (CAG)n repeat 
region was also used to determine XCI pattern using comparative quantitative 
detection of fluorescently labelled PCR products using intact and methylation 
sensitive restriction enzyme HpaII digested DNA templates. Amplicon size and 
inactivation ratios were determined by electrophoresis on an ABI Prism 377 
DNA Sequencer (PE Applied Biosystems, Foster City, CA, USA) under 
standard conditions and analysed by Genescan 2.1 software (PE Applied 
Biosystems). Rox 500® (PE Applied Biosystems) was used as an internal size 
standard. The shorter (S-CAG) and longer (L-CAG) allele of each individual, 
biallelic mean (CAG-BM, the arithmetic mean of allele lengths), weighted 
biallelic mean (CAG-WBM, mean allele length adjusted for relative activity of 
shorter and longer allele) and XCI difference (XCI-Dif, represents the gross 
difference from the 50:50 inactivation ratio) were used in statistical analyses. 
CAG-WBM was calculated using the following formula: 
CAG-WBM = [(S-Act/100) × S-CAG] + [(L-Act/100) × L-CAG], where S-Act 
and L-Act correspond to the percentage of cells with active shorter or longer 
CAG alleles, respectively. The area under the curve obtained by visualisation of 
PCR products was used for XCI pattern calculations using the following 
formula: 
XCI-Dif= |S-Act – L-Act|. 
For example, if S-Act and L-Act are both 50% inactive, the XCI-Dif is 0%, but 
if S-Act and L-Act are 90 and 10% inactive, respectively, the XCI-Dif is 80%. 
 
3.2.2. CCR5delta32 deletion genotyping (Study III) 
The CCR5delta32 deletion was detected using PCR, followed by visualisation of 
PCR products by electrophoresis on an agarose gel, which identified the 
following fragments: 189 bp (wild-type allele) and 157 bp (variant allele). 
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3.2.3. SNP genotyping (Studies III, IV & V) 
A total of 44 SNPs in 21 genomic regions were analysed.  
SNPs in TLR4 and MBL2 genes were detected using SNaPshot Multiplex 
primer extension (PE Applied Biosystems, Foster City, CA, USA). SNaPshot 
products were run on an ABI 3130xl Genetic Analyzer (PE Applied Bio-
systems), analysed using GeneScan 4.0 software (PE Applied Biosystems) and 
validated by direct sequencing.  
The MBL2 codon 54 polymorphism, as well as TLR2 Arg753Gln poly-
morphism were genotyped by RFLP analysis. The corresponding PCR products 
were digested overnight at 37°C using restriction enzymes BshNI and PstI, 
respectively. All restriction fragments were separated according to their length 
by gel electrophoresis and visualised under UV transillumination. 
Since the selected polymorphisms in the MBL2 gene are in strong LD, the 
genotyped SNPs were further combined to also include MBL2 haplotypes in the 
analysis. The first two positions in the haplotype are determined by poly-
morphisms in the promoter area and the third position in the haplotype, A or 
B/D, is a combination of the two polymorphisms in exon 1, with A indicating a 
wildtype allele in both positions and B/D representing a variant allele in the 
corresponding locus. Promoter haplotypes HY, LY and LX correlate with high, 
intermediate and low serum levels of MBL, respectively (Naito et al., 1999), 
while polymorphic structural variants (B/D) are associated with low levels or an 
absence of functional MBL (Sumiya et al., 1991; Lipscombe et al., 1992; 
Madsen et al., 1994). The two MBL2 variant alleles (B/D) in exon 1 were 
grouped together as allele O, and the two wild-type alleles were grouped as 
allele A (Garred et al., 2006). Overall 7 MBL2 haplotypes were present in groups 
analysed (HYPA, LYPA, LYQA, LXPA, HYPD, LYPB and LYPD), which 
formed 22 MBL2 combined genotypes. To facilitate interpretation of the data, 
simplified MBL2 haplotypes HYA (HYPA), LYA (LYPA, LYQA), LXA 
(LXPA) and O (HYPD, LYPB and LYPD) were used. Since MBL2 genotypes 
correlate with serum MBL levels, the latter were not measured and genotypes 
were divided into groups based on their estimated expression potential as 
follows: high-producing (HYA/HYA, HYA/LYA, LYA/LYA, HYA/LXA and 
LYA/LXA), low-producing (LXA/LXA, HYA/O and LYA/O) and MBL-
deficient (LXA/O and O/O) (Steffensen et al., 2000). 
All other SNPs were genotyped by Sequenom MassArray iPLEX Assay 
(Sequenom, San Diego, CA, USA). Genotypes were called automatically and 
confirmed manually using the MassARRAY Typer 4.0.22 software (Sequenom). 
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3.3. Statistical analysis 
Data for continuous variables are presented as mean ± SD, unless stated other-
wise. Allele frequencies were tested for deviations from the Hardy-Weinberg 
equilibrium. For all analyses, p value <0.05 was considered statistically 
significant. Statistical tendency or trend was considered to be present when 0.05 
< p < 0.1. 
The Student’s t-test, Wilcoxon rank sum test with continuity correction, χ2 
test or Fisher’s exact test were used to compare the distribution of studied 
characteristics in study groups. Linear and logistic regression analyses were used 
when adjustment for different confounding factors was necessary (details given 
in the Results and Discussion section). To consider the suitability of genetic 
variants associated with ovarian aging for use as markers of ovarian function, 
COS and IVF treatment, the leave-one-out cross-validation algorithm was 
applied and squared correlation between observed and predicted values (R2) or 
area under the ROC-curve (AUC) were calculated, respectively for logarithm 
transformed (continuous) variables or binary variables. 
For statistical analyses, the following software were used in different 
studies – The R2.0.0 and R 2.3.1 A Language and Environment (Free Software 
Foundation, Boston, MA, USA), Statistical Package for Social Sciences 17.0 


































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































4. RESULTS AND DISCUSSION 
4.1. Genetic susceptibility factors for PCOS  
(Studies I & II) 
4.1.1. Study design 
In this part of the study, we evaluated the INS VNTR and the AR CAG 
microsatellite for their association with PCOS. Patients with TFI but with 
regular menstrual cycles were used as controls in these studies. Therefore, the 
studies presented in this section represent classic genetic association studies that 
test whether particular allele(s) occur at a significantly different frequency 
among the patient group of interest compared to the control group. PCOS is a 
so-called complex disease, which means that it is caused by a combination of 
genetic and environmental factors and the individual contribution of each gene 
and genetic variant is small and individually insufficient to cause the disease. 
Both the AR CAG and INS VNTR were selected among genes likely involved in 
the disease pathogenesis based on the current knowledge about PCOS. On one 
hand, this approach lowers the number of potential comparisons and thus 
increases study power, but on the other hand it is hampered by our limited 
knowledge on the pathogenesis of complex diseases and by the heterogeneous 
phenotype typical for PCOS. One of the major pitfalls in PCOS candidate gene 
studies is the varying criteria used to diagnose PCOS (Goodarzi, 2007), 
therefore all the patients included in our studies were diagnosed according to 
the Rotterdam criteria (The Rotterdam ESHRE ASRM-Sponsored PCOS 
Consensus Workshop Group, 2004) which are currently the preferred criteria 
for diagnosis (Legro et al., 2013).  
 
4.1.2. INS VNTR, AR CAG and XCI 
Both the INS VNTR and AR CAG microsatellite together with XCI pattern were 
evaluated for association with PCOS. The distribution of INS VNTR genotypes 
was comparable in patients and in controls (Table 2), meaning that the INS 
VNTR is probably not associated with an increased PCOS risk. This is in 
concordance with large-scale studies analysing several data sets (Powell et al., 
2005; Song et al., 2014), but in disagreement with a meta-analysis claiming that 
the INS VNTR class III alleles increases PCOS risk (Yan et al., 2014). The 
different results of the meta-analyses may be explained by different i) study 
designs, ii) inclusion criteria that may result in a certain bias, and iii) analysis 
methodology. While Powell et al. (2005) conducted case-control, family-based 
association and quantitative trait analyses, Song et al. (2014) and Yan et al. 
(2014) conducted meta-analyses of 13 and 9 previously published datasets, 
respectively. It is also noteworthy that patient groups included in these meta-
analyses were diagnosed using various criteria (NIH criteria, ultrasound 
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symptoms, Rotterdam criteria) which could mean that due to patient hetero-
geneity these studies are actually not comparable.  
The studied AR CAG allelic characteristics (Table 2) did not differ between 
patients and controls, for example, both the AR CAG biallelic mean and 
weighted biallelic mean were on average approximately 21.5 repeats in PCOS 
patients and in controls. These results support the findings that the AR CAG is 
not a genetic susceptibility factor for PCOS (Wang et al., 2012; Rajender et al., 
2013; Zhang et al., 2013). The patients in this study had similar testosterone 
levels compared to the control group (Table 1 in Study II) and therefore 
represent the PCOS subphenotype that does not exhibit profound hyperand-
rogenism but rather presents with polycystic ovaries and menstrual cycle 
irregularities. Since there is evidence the AR CAG may contribute to the 
hyperandrogenemic aspect of the disease (Zhang et al., 2013; Peng et al., 2014), 
the AR CAG may modify the phenotype in patients with more pronounced 
hyperandrogenemic traits.  
 
Table 2. Genetic characteristics evaluated for association with PCOS. 
Characteristic PCOS Control 
INS VNTR genotypes n=30 n=75 
III/III 2 (6.7%) 7 (9.3%) 
III/I 10 (33.3%) 24 (32.0%) 
I/I 18 (60.0%) 44 (58.7%) 
AR CAG characteristics 
(mean no of repeats ± SD) 
n=32 n=79 
S-CAG  20.2±2.0 20.0±2.0 
L-CAG 22.8±1.9 23.1±2.4 
CAG-BM 21.5±1.6 21.6±1.8 
CAG-WBM 21.4±1.8 21.6±2.0 
XCI characteristics  
(mean percentage ± SD) 
n=23 n=63 
XCI-Dif 21.9±22.8 28.8±20.1 
SD – standard deviation, AR CAG – androgen receptor CAG microsatellite, CAG-BM – AR-CAG 
biallelic mean, CAG-WBM – AR CAG weighted biallelic mean, S-CAG – shorter AR CAG allele, 
L-CAG – longer AR CAG allele, XCI-Dif – X-chromosome inactivation difference represented by 






Figure 7. Distribution of XCI patterns and XCI-Dif values in study groups. The XCI-
Dif reflects the XCI pattern. For example, if both X-chromosomes are 50% inactive, the 
XCI-Dif is 0%, but if one is 90% and the other 10% inactive, the XCI-Dif is 80%.  
 
 
Although there is evidence that the XCI may be altered in PCOS women 
(Hickey et al., 2002; Dasgupta et al., 2010), the distribution of XCI pattern 
(represented by the absolute difference between the percentage of cells with an 
active longer or shorter CAG allele) in our study was similar in both groups 
(Table 2, Figure 7). Extreme XCI skewing (95:5) was seen in only one PCOS 
patient, while in the majority of patients and controls the XCI pattern was 
approximately 60:40 (Figure 7). Together with previous findings (Shah et al., 
2008; Schuring et al., 2012) it can be concluded that the XCI is not altered in 
PCOS women. However, since we studied the XCI phenomenon only in 
peripheral blood samples, and the XCI pattern can vary between tissues (Gale et 
al., 1994), the possibility that the XCI pattern is skewed in tissues of importance 
to PCOS pathogenesis (pituitary, ovarian tissues, etc) cannot be excluded. 
The major limitation for the abovementioned studies was the modest sample 
size, which can result in false-negative findings because, as already mentioned, 
the effect of each genetic variant in the pathogenesis of PCOS is small and large 
study groups are needed to reach the necessary statistical power (Diamanti-
Kandarakis and Piperi, 2005). Furthermore, our patient group represents only 
those PCOS patients who have infertility issues. Overall, it seems that the INS 
VNTR and AR CAG together with the XCI pattern are not major susceptibility 
factors for PCOS, which has also been shown by several other studies (Powell 
et al., 2005; Wang et al., 2012; Zhang et al., 2013; Song et al., 2014). However, 
like with many other candidate gene association studies, the results of the 
current analysis must be interpreted bearing in mind that PCOS is a syndrome 
with a great phenotypic heterogeneity, and although we did not find any 
associations with the studied variants, in a different subset of patients the 
associations may be present. 
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4.2. Prevalence of C. trachomatis-related TFI  
(Study III) 
Since chlamydia-related infertility is one of the few forms of infertility that 
could be avoided, a better estimation of the prevalence of chlamydia-related TFI 
in Estonia could give valuable directions for future healthcare strategies. A 
nation-wide multicentre study would be the best study design for this purpose, 
but given the overall lack of data on TFI prevalence in Estonia and the fact that 
infertile women are treated in five major hospitals/clinics (Tonsiver et al., 
2013), data from a single centre study could also adequately reflect the current 
situation in Estonia.  
In order to determine C. trachomatis infection status in the TFI group, if 
possible, data from antibody analysis was combined with data extracted from 
medical records. We found that the prevalence of C. trachomatis-specific IgG 
antibodies was lower in the control group (17.8%), which is similar to that 
previously reported for fertile aged Estonian women (20.2%) (Kibur et al., 
2000). On the contrary, approximately half (48.4%) of the patients with TFI had 
corresponding antibodies (Figure 8). 
If additional data from medical records was taken into account, 58.7% of 
women with TFI were considered positive for C. trachomatis (CT+). A high 
prevalence of C. trachomatis seropositivity among women with TFI was to be 
expected, as C. trachomatis infection is one of the main causative factors of TFI 
(Paavonen and Eggert-Kruse, 1999). In addition to causing TFI, C. trachomatis 
infection can have detrimental effects on pregnancy outcome (Linhares and 
Witkin, 2010) and cumulative non-IVF pregnancy rate (Keltz et al., 2013), 
meaning that genital chlamydia infection can have a negative impact on human 
fertility that involves more than straightforward tissue damage.  
 
 




According to these results, approximately half of all TFI cases in Estonia can be 
categorised as having C. trachomatis-related TFI, which is in good correlation 
with published estimates (Price et al., 2012). Since acquired infertility due to 
infections is practically the only form of infertility that could be avoided and the 
prevalence of genital chlamydia among young females is among the highest in 
Europe (Redmond et al., 2015), preventive measures (sexual health training, 
screening strategies for target groups) and timely interventions could help to 
significantly reduce the number of women suffering from chlamydia-related 
infertility in Estonia.  
 
4.3. Genetic susceptibility factors for TFI  
(Studies III & IV) 
4.3.1. Study design 
Identifying the genetic susceptibility factors of C. trachomatis infection and 
tubal damage could give further knowledge on the immunopathogenesis of 
genital infections and host-pathogen interactions, which in turn can help to 
identify those individuals at risk for developing serious complications. Similarly 
to PCOS, the genetic susceptibility factors for TFI have been thus far sought 
using the candidate gene approach (Morre et al., 2009b). The most common 
study designs include a) comparing CT+ (either DNA or antibody positive) 
individuals with CT− individuals, and b) comparing CT+ patients with CT+ 
individuals with a different course of infection (Morre et al., 2009b). In the 
studies presented in this section, women with TFI were compared to controls 
(fertile women and women representing the general population). Additionally, 
women with tubal damage (ectopic pregnancy) but without infertility 
complaints were enrolled in Study IV to help establish whether the selected 
genetic variants are associated merely with tubal damage, or also have a certain 
impact on fertility as such. In both studies, the patient and control groups were 
also divided according to their C. trachomatis status, as the mechanisms of 
pathogenesis may differ in chlamydia-related TFI and TFI not involving a 
chlamydia infection. 
According to Morré et al, the most important variables to consider in the 
analysis stage include clear ethnic background of study population (due to 
varying SNP allele frequencies in different populations), clinical definition of 
C. trachomatis status and correct definition of tubal pathology (Morre et al., 
2009b). All studied TFI patients were Estonians (Caucasian) and all control 
group DNAs were obtained from the Estonian Genome Centre of the University 
of Tartu, which is a population-based biobank where the vast majority of 
participants are also Caucasians (http://www.geenivaramu.ee/en/about-us). This 
means that all individuals in studies III and IV come from the same region, 
share a similar racial (and very likely a similar ethnic) background, therefore 
this factor is unlikely to influence the results. In the patient group, TFI was 
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diagnosed either by hysterosalpingography or by diagnostic laparoscopy which 
are both generally accepted and recommended methods for assessing tubal 
pathology (Practice Committee of American Society for Reproductive Medicine, 
2012). For the control groups, the medical history in the biobank is recorded 
according to the ICD-10 classification, and all individuals with diagnosis code 
N97.1 (female infertility of tubal origin) were excluded from the analysis. Since 
the medical history relies on self-reported data, the possibility that some women 
with TFI were also accidentally included in the control group representing the 
general population cannot be excluded. The control group also included 200 
fertile controls, who had at least 2 children and were therefore unlikely to suffer 
from infertility. In study IV, we studied an additional group of women from the 
Estonian Genome Center who had tubal damage (ectopic pregnancy) but no 
self-reported infertility complaints. This group was selected because similarly to 
TFI, the main risk factors for ectopic pregnancy include sexually transmitted 
infections, tubal infection or pelvic adhesions, and the majority (~90%) of 
ectopic pregnancies are located in the fallopian tubes (Practice Committee of 
the American Society for Reproductive Medicine, 2013). In these women, the 
presence of tubal damage was not confirmed by hysterosalpingography or 
laparoscopy, and the diagnosis of ectopic pregnancy (ICD-10 O00 for ectopic 
pregnancy or O00.1 for tubal pregnancy) was considered as sufficient evidence 
for the presence of tubal damage or dysfunction.  
C. trachomatis status in all studied groups was determined by testing the 
serum samples for the presence of C. trachomatis-specific IgG antibodies, 
which generally denote previous and resolved infections (Debattista et al., 
2003). When possible, C. trachomatis infection status was determined by 
combining both medical history and IgG antibody analysis, since C. 
trachomatis-specific IgG antibodies are detectable in serum for up to 8 years 
(Debattista et al., 2003). Of course, the self-reported data on chlamydia 
infection may not be most accurate due to recall bias or because in some 
patients the infection can clear spontaneously (Geisler, 2010). Using this 
combined approach we most likely identified the vast majority of individuals 
who have had a genital chlamydia infection, but it cannot be excluded that some 
women were mistakenly classified as CT−. 
Polymorphic variants in the CCR5, TLR2, TLR4 and MBL2 genes were 
tested and evaluated for their association with TFI.  
 
4.3.2. CCR5, TLR2 and TLR4 
The distribution of CCR5delta32 deletion, TLR2 Arg753Gln, TLR4 Asp299Gly 
and Thr399Ile genotypes did not differ between TFI patients and controls, or 
between CT+ and CT− groups (Table 3).  
A role for CCR5 in modulating the likelihood of tubal pathology has been 
proposed (Barr et al., 2005); however, our results do not support this notion. 
The frequency of variant allele carriers among controls and infertile women was 
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similar in both studies (~20%), but Barr and colleagues reported a remarkable 
difference in CCR5delta32 carriership when comparing subfertile CT+ women 
with and without tubal pathology (7% vs. 31%). Our study did not include a 
subfertile CT+ control group and this could be one of the reasons for contrasting 
results, stressing the importance of group selection when studying the genetic 
background of TFI. Although a recent study with a design similar to ours also 
found no differences in CCR5delta32 distribution (Mania-Pramanik et al., 2011), 
these results must be interpreted with care as the frequency of CCR5delta32 
variant allele carriers shows great geographic variation and was very low in this 
study population (2%).  
Several TLRs have been studied in the context of tubal pathology 
development (Darville et al., 2003; den Hartog et al., 2006b), but the results 
have been inconclusive. In our study, the frequency of studied polymorphisms 
in TLR2 and TLR4 did not differ between studied groups, which is in line with 
results from similar studies (Morre et al., 2003; den Hartog et al., 2006b; Karimi 
et al., 2009). Therefore, common genetic variants in TLR2 and TLR4 are 
probably not a major susceptibility factor for TFI. 
 
Table 3. Distribution of CCR5, TLR2 and TLR4 genotypes in studied groups. 
Polymorphism 
Genotype 










































































































CT – Chlamydia trachomatis; TFI – tubal factor infertility 
 
As a conclusion, our results show that genetic variants in CCR5, TLR2 and 
TLR4 are not major susceptibility loci for TFI. However, in the future it could 
be worthwhile to consider SNP interactions and conduct a burden analysis, as 
there is evidence that carriage of two or more SNPs in genes related to TLR 
signalling can increase the risk of developing tubal pathology following 
chlamydia infection (den Hartog et al., 2006b).  
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4.3.3. MBL2 
When tested separately, no associations were observed for MBL2 −221 X/Y, +4 
P/Q, codon 52 and codon 54 polymorphisms, whereas the distribution of  
MBL2 −550 H/L genotypes was significantly different between TFI patients and 
controls (p < 0.05), which correlates with the differential distribution of MBL2 
combined genotypes. The first two positions in the combined genotype are 
determined by polymorphisms in the promoter area and the third position, A or 
B/D, is a combination of the two polymorphisms in exon 1, with A indicating a 
wildtype allele in both positions and B/D representing a variant allele in the 
corresponding locus. When MBL2 SNPs were evaluated in the context of 
combined genotypes, both Study III and IV showed the high-producing HYA/ 
HYA genotype was more frequent in TFI patients than in controls (p<0.05 in 
both studies) (Figure 9). However, study IV also showed the HYA/HYA 
genotype was more frequent in women with TFI compared to women with tubal 
damage but no infertility (p<0.05) (Figure 9).  
According to our results, the high-producing HYA/HYA genotype is a risk 
factor for TFI. The HYA/HYA genotype has been associated with MBL hyper-
production (Madsen et al., 1995; Matsushita et al., 2001) and susceptibility to 
primary biliary cirrhosis (Matsushita et al., 2001), which supports the ‘MBL 
paradox’ hypothesis (Dommett et al., 2006). This hypothesis states that very 
high MBL levels may be disadvantageous for two reasons: a) certain intra-
cellular parasites may benefit from increased complement activation associated 
with very high MBL levels; and b) excessive complement activation may lead 
to immunopathological host damage (Dommett et al., 2006). Therefore, the 
preliminary conclusion was that excessive complement activation and subsequent 
tissue damage may very well be the mechanism linking the high-producing 
HYA/HYA genotype with TFI.  
 
Figure 9. Frequency of MBL HYA/HYA genotype in studied groups. Data from Study IV. 
13
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Interestingly, study IV showed the HYA/HYA genotype frequency in the ectopic 
pregnancy group (women with tubal damage but no infertility) was similar to 
the control group (Figure 9). If the HYA/HYA genotype was associated only 
with tubal damage, we would expect to see similar frequencies in both patient 
subgroups, so this finding is contradictory to our initial conclusion. One 
differentiating characteristic of the two patient groups is that unlike the TFI 
group, the ectopic pregnancy patients had no infertility complaints in their 
anamnesis and additional analysis of their reproductive history (data not shown) 
revealed that they had had an average of 4 pregnancies per woman. Unfor-
tunately, it is not known whether they had had any pregnancies after being 
diagnosed with ectopic pregnancy; however, spontaneous conception is very 
likely after treatment of ectopic pregnancy, regardless of the treatment option 
(medical or surgical) (Fernandez et al., 2013). Although increase in MBL levels 
and MBL complement pathway activity is a necessary part of maintaining 
pregnancy (van de Geijn et al., 2007b), high-producing genotypes or higher 
MBL levels have also been linked with conditions associated with excessive 
complement action and inflammatory reactions at the maternal-fetal interface, 
such as pre-eclampsia (Sziller et al., 2007a). Considering the role of MBL in 
normal pregnancy and adverse pregnancy outcomes, it is possible that MBL 
genotypes and levels also play a part in embryo implantation. Indeed, higher 
MBL levels have been associated with both unexplained infertility (Oger et al., 
2009) and low implantation rates (Chaouat et al., 2009), demonstrating the role 
of MBL in embryo implantation and implantation failure. Furthermore, deposits 
of one particular isoform of MBL at the implantation sites are linked with 
pregnancy failure in mice (Chaouat et al., 2009), indicating that higher MBL 
levels and complement deposits both in mice and humans may lead to adverse 
pregnancy outcome (Chaouat et al., 2009). Even though our TFI group is 
primarily diagnosed with tubal infertility, the additional component of im-
plantation failure or incomplete implantation cannot be ruled out. Unfortunately 
MBL2 genotype frequencies were not determined in previous studies (Chaouat et 
al., 2009; Oger et al., 2009).  
To further analyse the associations between genetic variants and tubal 
damage and because we were first and foremost interested in genetic sus-
ceptibility factors for chlamydia-related TFI, the studied groups (controls and 
women with tubal damage and with/without infertility) were divided according 
to their CT-status. We found the high-producing HYA/LYA genotype was more 
prevalent in the CT+ control group (p<0.05 in both studies) (Figure 10A), 
suggesting a protective effect associated with this genotype, which can mean 
that a certain genotype or MBL level can provide the optimal immune response 
during C. trachomatis infection. The heterozygous HYA/LYA is associated with 
a somewhat lower level of MBL expression compared to HYA/HYA 
homozygotes and similar levels compared to LYA/LYA homozygotes (Madsen 
et al., 1995).  
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A)       B) 
  
 
Figure 10. A) Frequency of MBL HYA/LYA genotype, and B) frequency of MBL low-
producing genotypes in studied C. trachomatis+ groups. Data from Study IV. 
 
 
In addition, we found that the low-producing MBL2 genotypes as a cluster are 
more common among CT+ TFI patients (p<0.05 in both studies) (Figure 10B), 
indicating increased susceptibility to tubal damage after genital chlamydia 
infection. Contrary to previously reported results (Sziller et al., 2007c), our 
analysis showed no difference in codon 54 or MBL-deficient genotype 
distribution among C. trachomatis-positive patients and controls. Previously, 
the MBL2 codon 54 heterozygous A/B genotype has been associated with 
decreased IVF success rate in women with TFI (Spandorfer et al., 2003), 
however, the possible association with other MBL2 genotypes was not 
evaluated. The codon 54 A/B genotype is also a low-producing genotype and 
taken together, these data indicate that MBL2 genotypes with intermediate 
protein expression pattern may be associated with decreased IVF success rates.  
We identified several MBL2 genotypes that may increase, or on the contrary, 
decrease the susceptibility to TFI. However, further studies are needed to decide 
whether these different genotypes have any functional consequences during C. 
trachomatis infection or facilitate tissue damage in the fallopian tubes, and also 
whether similar results are observed in independent studies. In addition, a study 
designed specifically for evaluating associations between pregnancy outcome 
and MBL2 genotypes should be conducted in order to further elucidate how 
MBL2 genotypes modify female fertility. TFI genetic susceptibility studies in 
general may benefit from larger study cohorts and international collaborations 
to identify variants with smaller effects and perhaps use a pathway approach in 




4.4. Genetic variants related to ovarian aging – 
association with ovarian function,  
COS and IVF treatment parameters (Study V) 
4.4.1. Study design and studied parameters 
In study V, the genetic variants previously associated with age at natural 
menopause (Stolk et al., 2012) and common polymorphisms in the FSHB and 
FSHR genes (in total 36 SNPs) were evaluated for their association with early 
follicular phase characteristics and ovarian stimulation and IVF outcome 
parameters in a cohort of women undergoing IVF treatment. The most popular 
study design for evaluating genotype effects on ovarian stimulation outcome 
includes the use of data from women undergoing IVF-COS for infertility 
treatment. The use of assisted reproduction treatment data presents numeral 
statistical challenges, as the process involves several interdependent steps and 
often women undergo more than one treatment cycle. For data analysis, usually 
all but one cycle are discarded, resulting in decreased statistical power, 
especially in typical single-site IVF studies (Missmer et al., 2011). The major 
shortcomings in IVF data analysis include quantifying statistical significance 
without evaluating the magnitude of effect, ignoring confounding factors, and 
using only a subset of the data at hand. Thus, several sophisticated statistical 
models have been proposed to make full use of the collected multicycle data 
(Missmer et al., 2011). In order to fully use the data available and increase study 
power, we included all treatment cycles for women who underwent two or more 
treatment cycles during the study period. For data analysis, generalized linear 
mixed models with logit or logarithm link function were used and all tested 
models were adjusted for appropriate confounding factors. The effect of 
repeated measurements from the same woman was considered as a random 
effect in statistical models.  
The distribution of different studied parameters is shown in Table 4. The 
study included data for a total of 471 treatment cycles from 306 women [age 
33.8±4.4 years in first cycle, 34.2±4.4 years across all treatment cycles; body 
mass index (BMI) 22.6±3.2]. 123 women underwent two or more treatment 
cycles during the study period, and on average, the participants had undergone 
0.9±1.2 treatment cycles before entering this study. The distribution of 
diagnoses for infertility was as follows: TFI (42.5%), male factor (29.7%), 
endometriosis (10.1%), unexplained (6.9%), and other (10.5%). For one 
participant, the diagnosis was unknown. Ultrasound data for assessing ovarian 
parameters (ovarian volume and antral follicle count) was available for 135 
participants, while a blood sample for measuring early follicular phase FSH 





Table 4. Main characteristics of study participants and analysed parameters in Study V. 








Early follicular phase 
parameters 
Mean ovarian volume (mL) 














rFSH total (IU) 
OPU follicles 
Oocytes retrieved 



















FSH – follicle stimulation hormone, ICSI – intracytoplasmic sperm injection, IVF – in vitro 
fertilisation, OPU – ovarian puncture, rFSH – recombinant FSH, and SD – standard deviation 
4.4.2. Genetic factors associated  
with early follicular phase parameters 
In this section, associations between selected genetic variants and early follicular 
phase FSH levels, antral follicle count and ovarian volume were evaluated.  
Early follicular phase FSH level analyses were adjusted for age, BMI, cycle 
day, mean follicle count and for any ovarian surgery. We found the early 
follicular phase FSH levels were significantly lower in rs2303369 (FNDC4) CC 
homozygotes (p<0.05, Figure 11A). This finding deserves special attention, 
especially when planning future studies aimed at revealing the genetic 
regulation of FSH action. rs2303369 is in LD with other SNPs in the adjacent 
GCKR (glucokinase regulator) gene, and the FNDC-GCKR locus has been 
associated with levels of albumin (Franceschini et al., 2012) and C-reactive 
protein (Ridker et al., 2008), indicating that the locus may have a more general 
effect on the levels of different serum components, including FSH. This means 
that when studying the genetic factors affecting FSH levels in circulation, 
variants other than those directly in FSHB region should also be considered. 
In addition, early follicular phase FSH levels were significantly lower in 
rs611246 (FSHB) AA homozygotes (p<0.05, Figure 11B). Our study included 
the four SNPs representing the FSHB core haplotypes, but as these SNPs were 
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in complete LD, data is shown only for rs611246. As far as we know, the effect 
of FSHB core haplotypes on hormone levels is unknown. In our study, women 
with the T-allele had slightly higher FSH values (8.5 IU/L), which still 
remained in the normal range for follicular phase (3.5–12.5 IU/L). The 
polymorphisms forming the haplotype, rs611246 among them, are most likely 
regulatory SNPs (Grigorova et al., 2007), which may affect transcription levels 
or stability and thereby also protein levels, but their exact functional 
significance is yet to be elucidated. 
A)     B) 
 
 
Figure 11. Early follicular phase FSH levels according to A) rs2303369 (FNDC4), and 
B) rs611246 (FSHB) genotypes. Data presented as least square means (± standard error) 
of the studied trait; from linear regression adjusted for age, BMI, cycle day, mean 
follicle count, previous ovarian surgery. 
 
None of the tested genetic variants was associated with ovarian volume. How-
ever, antral follicle count was significantly higher in individuals carrying the G-
allele of rs1277460 (FSHR) and also in rs6166 (FSHR) GG homozygotes (p<0.05, 
Figure 12) (antral follicle count analyses were adjusted for age, any ovarian 
surgery, mean ovarian volume, early follicular phase FSH and estradiol values).  
A)     B) 
 
Figure 12. Mean antral follicle count according to A) rs1277460 (FSHR), and B) 
rs6166 (FSHR) genotypes. Data presented as least square means (± standard error) of 
the studied trait; from linear regression adjusted for age, previous ovarian surgery, mean 
ovarian volume, early follicular phase FSH and estradiol values. 
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Polymorphisms in the FSHR gene, especially rs6165 and rs6166, have 
thoroughly been studied in the context of ovarian reserve but the results are 
somewhat conflicting probably due to heterogeneity of study groups (reviewed 
in Simoni and Casarini, 2013). In our study, the two SNPs showed complete 
LD, therefore data are presented only for rs6166, which was associated with 
mean antral follicle count; however, the individual genotype effects were 
unclear. Unfortunately the genotyping of FSHR promoter polymorphism 
rs1394205 (–29G>A) failed (call-rate <90%), thus it was not possible to use the 
analysis methodology recommended by Simoni et al (Simoni and Casarini, 
2013), that is the combined analysis of rs6166 and rs1394205 in FSHR, and 
rs10835638 in FSHB promoter. The grouping of these three SNPs results in 27 
combinations that associate with different FSH levels and FSHR activity, and 
failure to consider the interactions of these SNPs may cause incorrect results 
(Simoni and Casarini, 2013). rs1277460 represents one of the less-studied 
FSHR polymorphisms, but it has been associated with female fertility 
(Kuningas et al., 2011). 
In conclusion, several of the analysed SNPs in various genes (FSHB, FSHR, 
FNDC4) were associated with early follicular phase parameters (early follicular 
phase FSH levels and mean antral follicle count). However, our study included 
women of different age and with various reasons for infertility, and therefore 
may not represent the ideal cohort for studying such parameters. Thus, further 
studies are needed to clarify if the effects seen in this study also apply to healthy 
women. 
 
4.4.3. Genetic factors associated with COS outcome 
To test the statistical significance of effects of preselected genotypes on 
repeatedly measured ovarian stimulation parameters (total amount of rFSH 
administered, number of follicles and oocytes obtained on ovarian puncture, the 
amount of rFSH administered per retrieved oocyte), generalized linear mixed 
models with logarithm link function were fitted. All tested models were 
adjusted for appropriate confounding factors (age, diagnosis and stimulation 
protocol used, and also for the amount of rFSH used in OPU follicle/retrieved 
oocyte analysis) and the effect of repeated measurements from the same woman 
was considered as a random effect. The distribution of analysed characteristics 
is shown in Table 4. 
Three SNPs from our selection [rs10852344 (intergenic), rs12461110 
(NLRP11), and rs4246511 (RHBDL2)] apparently modulate the amount of rFSH 
necessary for ovarian stimulation (Figure 13A-C). Individuals with the minor 
homozygotic genotype at rs10852344 and rs12461110 needed significantly 
larger amounts of rFSH during stimulation, whereas minor homozygotic 
genotype at rs4246511 seems to be associated with smaller doses of rFSH (all 
p<0.05). The same SNP also has an impact on the amount of rFSH necessary 
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for retrieving one oocyte during stimulation, as do rs11668344 in TMEM150B 
and rs2153157 in SYCP2L (p<0.05) (Figure 13D-F).  
 
A)              B)                     C) 
 
 
D)                E)     F) 
 
 
Figure 13. Total amount of rFSH used according to A) rs10852344 (intergenic), B) 
rs12461110 (NLRP11) and C) rs4246511 (RHBDL2) genotypes, and the amount of 
rFSH administered per retrieved oocyte according to D) rs11668344 (TMEM150B), E) 
rs2153157 (SYCP2L) and F) rs4246511 (RHBDL2) genotypes. Data presented as least 
square means (± standard error) of the studied trait 
 
 
RHBDL2 [rhomboid, veinlet-like 2 (Drosophila)] is an intramembrane serine 
protease from the rhomboid family that releases soluble growth factors by 
proteolytic cleavage of membrane-bound substrates, including EGF, ephrins 
and thrombomodulin (reviewed by Etheridge et al., 2013). The EGF network is 
involved in many aspects of human reproduction, including ovarian steroido-
genesis and oocyte maturation (Jamnongjit et al., 2005). TMEM150B is a 
member of the damage-regulated autophagy modulator family of membrane-
spanning proteins, while NLRP11 is a cytoplasmic protein implicated in the 
activation of proinflammatory caspases. Both of these genes have repeatedly 
come up in studies of menopause timing (Stolk et al., 2009; Chen et al., 2012; 
Stolk et al., 2012; Perry et al., 2013; Shen et al., 2013; Chen et al., 2014), 
indicating their influence on the trait is similar and conserved among women of 
different ethnicities; however, the exact mechanism of effect remains unclear. 
The major alleles of these SNPs were associated with decreased amount of total 
rFSH/rFSH per oocyte, and also with increased age at menopause (Stolk et al., 
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2012), suggesting the proteins might somehow mediate the action of FSH on 
follicular maturation, which is supported by the fact that the NLRP proteins are 
important for oogenesis (McDaniel and Wu, 2009). rs2153157 (SYCP2L; 
synaptonemal complex protein 2-like) has repeatedly been associated with age 
at natural menopause (He et al., 2009; Stolk et al., 2012; Carty et al., 2013) and 
studies from mice show that SYCP2 is necessary for synaptonemal complex 
assembly and chromosomal synapsis during male meiosis, and furthermore, 
female SYCP2 knockout mice show signs of subfertility and reduced litter size 
(Yang et al., 2006). rs2153157 minor homozygotes also need significantly 
smaller amounts of rFSH/oocyte, which combined with the fact that the minor 
allele increases age at menopause (Stolk et al., 2012), indicates that the minor 
allele carriers have a better ovarian reserve. rs10852344 is located in an 
intergenic region and is surrounded by three genes (GSPT1, SNX29 and 
TNFRSF17) that harbour many SNPs that are in LD with rs10852344. The 
nearest gene is GSPT1 (G1 to S phase transition 1) that encodes the eRF3a 
protein involved in chromosomal segregation and cytokinesis during mitosis.  
Both the numbers of OPU follicles and oocytes retrieved were associated 
with two SNPs – rs4886238 (TDRD3) and rs7606918 (METAP1D) (Figure 14). 
The minor homozygotic genotype at rs4886238 and the major homozygotic 
genotype at rs7606918 result in smaller numbers of OPU follicles (p<0.05) and 
retrieved oocytes (p<0.05). In addition, rs3736830 (KPNA3) and rs2268363 
(FSHR) were associated with the number of OPU follicles (Figure 14), but not 
with the number of retrieved oocytes. 
Of these three SNPs, rs4886238 (TDRD3; tudor domain containing 3) is 
probably the most interesting in this framework because TDRD3 interacts with 
the FMR1 protein (Linder et al., 2008) implicated in the development of POI 
(Sullivan et al., 2011). In our study the ovarian stimulation in rs4886238 G-
allele carriers resulted in more follicles and oocytes, whereas previously the 
same allele was associated with earlier age at menopause (Stolk et al., 2012). 
These two results indicate that the ovarian pool is depleted quicker in women 
carrying the G-allele. Not much is known about rs3736830 in KPNA3 
(karyopherin alpha 3, also known as importin α4), which belongs to importin 
alpha family and mediates nuclear protein import. Importin α4 mRNA is 
expressed in rodent testis (Hogarth et al., 2006) and importin α4 protects against 
oxidative stress in murine spermatids (Young et al., 2013), further connecting 
the protein with germ cell development. However, until now the association 
with menopause timing was the only link with female reproductive biology, as 
is the case with rs7606918 in METAP1D (methionyl aminopeptidase type 1D), 
a methionyl aminopeptidase found in mitochondria and often overexpressed in 
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Figure 14. Number of OPU follicles according to A) rs3736830 (KPNA3), B) 
rs4886238 (TDRD3), C) rs7606918 (METAP1D) and D) rs2268363 (FSHR) genotypes 
and the number of obtained oocytes according to E) rs4886238 (TDRD3) and F) 
rs7606918 (METAP1D) genotypes. Data presented as least square means (± standard 
error) of the studied trait. 
 
 
The FSHR gene is currently the most studied genetic factor with regard to IVF-
COS (Altmäe et al., 2011; Simoni and Casarini, 2013) and the rs6165 and 
rs6166 SNPs have been associated with reduced IVF-COS outcome, elevated 
FSH administration and lower clinical pregnancy rate (reviewed by Altmäe et 
al., 2011). However, the clinical relevance of the FSHR polymorphisms alone is 
limited (Simoni and Casarini, 2013) and recent studies have proposed that 
rs6165 and rs6166 polymorphisms may be useful for distinguishing women 
undergoing IVF-COS who are at a risk of extreme ovarian response one way or 
the other (poor responders vs. ovarian hyperstimulation syndrome) (Yan et al., 
2013; Pabalan et al., 2014), rather than predicting the entire spectrum of ovarian 
response. Our study did not find any associations between IVF-COS parameters 
and rs6165 and rs6166 in the FSHR, but instead, the rs2268363 in FSHR was 
linked with the number of OPU follicles. This SNP has previously come up in a 
GWA study of erectile dysfunction (Kerns et al., 2010). These results suggests 
that the range of SNPs having an effect on FSH functioning goes beyond the 
most studied rs6165 and rs6166 and future studies should include other SNPs 
from the FSHR region and perhaps even consider SNP interactions both in the 
FSHR region and with SNPs in the FSHB gene (Simoni and Casarini, 2013). 
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While a genome-wide hypotheses-free approach would be the best for 
discovering genetic associations, it cannot always be applied. To the best of our 
knowledge, the study by van Disseldorp et al (van Disseldorp et al., 2011) is so 
far the only IVF-COS GWAS conducted. Their study involved 102 women 
undergoing IVF treatment but unfortunately no genetic variant significantly 
correlated with parameters of IVF-COS and the authors concluded that it is 
possible that the GWAS methodology may dismiss variants with smaller effects 
and due to GWAS stringent analysis criteria, the study would need to be 
repeated in a much larger study cohort (van Disseldorp et al., 2011). However, 
since the very large and rather homogenous study cohorts suitable for GWAS 
are difficult to achieve in a single-centre IVF setting, an (international) multi-
centre effort is needed to achieve the necessary sample size for conducting a 
successful GWAS. Until then, other approaches have to be used for detecting 
potential biomarkers for IVF-COS traits. A pre-selection (based on the 
association with the timing of age at natural menopause) used in Study V helped 
to narrow down the number of tested markers and thus to bypass the analysis 
bottleneck associated with GWAS. To conclude, these results shed some light 
on how the genes associated with female reproductive aging exert their effect, 
providing new directions for future research. Furthermore, the results show that 
genetic variants associated with reproductive aging are good candidates for 
searching IVF-COS markers. 
 
4.4.4. Genetic factors associated with IVF outcome 
To evaluate the effect of genetic variants on IVF outcome parameters (bio-
chemical and clinical pregnancies), generalized linear mixed models with logit 
link function were fitted and analyses were adjusted for age, diagnosis, endo-
metrial thickness, number of previous IVF treatments, number of good quality 
embryos, number of transferred embryos and type of IVF procedure. In 
addition, the effect of repeated measurements from the same woman was 
considered as a random effect. The values for IVF outcome parameters are 
shown in Table 4. 
rs10852344 (intergenic) and rs2153157 (SYCP2L) were associated with both 
biochemical and clinical pregnancies (Figure 15). rs10852344 minor 
homozygotes were significantly less likely to achieve biochemical or clinical 
pregnancy (p<0.05), whereas in the case of rs2153157, individuals carrying the 
minor allele were more likely to get a positive treatment outcome (Figure 15). 
The positive effect of the T-allele of rs2153157 (SYCP2L) on clinical pregnancy 
rates can stem directly from improved ovarian reserve or be associated with the 
role the synaptonemal complex plays in preventing chromosome segregation 
errors and embryo aneuploidy – a major cause of implantation failure and early 
miscarriage. A similar mechanism of action can be suspected for rs10852344, as 
the T-allele carriers have increased chances for both biochemical and clinical 
pregnancy and also need less rFSH during stimulation. As mentioned above, 
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rs10852344 is near the GSPT1 that encodes the eRF3a protein, which is 
involved in chromosomal segregation and cytokinesis during mitosis, and 
highly expressed in blastocysts (Adjaye et al., 2007), suggesting the protein 
might be important for early embryonic development, which supports the 
present results.  
While the C-allele of rs4246511 in RHBDL2 increased the amount of rFSH 
used during stimulation and necessary for retrieving one oocyte, the T-allele 
was associated with a decreased chance of clinical pregnancy (Figure 15). 
RHBDL2 substrates include thrombomodulin, which has been associated with 
embryo implantation (Dassen et al., 2007; Singh et al., 2011). The fact that the 
effects of rs4246511 detected in this study are somewhat conflicting – women 
with the T-allele respond better to ovarian stimulation, and enter menopause 
later (Stolk et al., 2012), yet have reduced chances of pregnancy – suggests the 
observed results are manifested via different pathways in the ovary and in the 
endometrium. However, since the rs4246511 has been scarcely studied in 
humans, further studies are needed to clarify the role of rs4246511 and 
RHBDL2 in human reproduction.  
 
                               A)             B) 
 
 
            C)     D)           E)                 F) 
 
Figure 15. Probability of biochemical pregnancy according to A) rs2153157 (SYCP2L) 
and B) rs10852344 (intergenic) genotypes, and probability of clinical pregnancy 
according to C) rs10852344 (intergenic), D) rs2153157 (SYCP2L), E) rs4246511 
(RHBDL2) and F) rs611246 (FSHB) genotypes. Data presented as estimated 
probabilities (± standard error) of studied parameters.  
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In our study, the individuals carrying the FSHB rs611246 T-allele were more 
likely to achieve clinical pregnancy (Figure 15). The core haplotypes identified 
in the FSHB gene region have been associated with conception success in 
healthy females (Grigorova et al., 2007). Interestingly, in this study the SNPs 
forming the haplotypes had an effect on the probability of successful (IVF) 
clinical pregnancy. Grigorova et al. (2007) speculated that FSHB gene variants 
may influence female conception efficiency, and our results seem to support 
this notion, although contrary to Grigorova et al, our study included only 
infertile couples. In our study, women with the T-allele had slightly higher FSH 
values (8.5 IU/L), which still remained in the normal range for follicular phase 
(3.5–12.5 IU/L), and at the same time had an increased chance of clinical 
pregnancy compared to AA homozygotes. Whether the positive influence on 
clinical pregnancy rates is achieved through relatively higher yet normal FSH 
levels or some other mechanism is currently unclear. 
The results of this section highlight the fact that ovarian reserve/IVF-COS 
effectiveness and chances of a successful pregnancy are closely related, as 
several of the markers that associated with IVF outcome parameters were also 
associated with IVF-COS/early follicular phase parameters. Although the most 
apparent explanation for these associations would be the underlying effect of 
woman’s age, which has a profound effect on both traits (van Loendersloot et 
al., 2010), this most likely is not the case, as the woman’s age was considered as 
a cofactor in all analyses. For two variants that were linked with several 
parameters – rs2153157 (SYCPL2) and rs4246511 (RHBDL2) – two alternative 
modes of action were proposed that could explain both the associations with 
IVF-COS and IVF treatment outcome parameters, but for the rest, not enough 
data is currently available to say anything conclusive about their role in female 
fertility and further studies are definitely needed. 
 
 
4.5. Genetic variants related to ovarian aging – 
potential markers for ovarian function, controlled 
ovarian stimulation and IVF treatment? (Study V) 
Although numerous genetic variants have been associated with traits reflecting 
the ovarian function and concomitantly proposed as suitable markers, their 
actual predictive ability is rarely addressed and therefore unknown. Statistical 
associations obtained in retrospective studies can give valuable hints about the 
function of the studied variant, yet they are insufficient for assessing the actual 
clinical validity of this variant. A prospective clinical study would be the 
preferred method for assessing the true predictive power for any potential 
biomarker, but at the same time it is also a very time-consuming method, and in 
certain cases where differential treatment would be applied according to the 
genotype (such as rFSH dosing in IVF-COS), could also pose serious ethical 
concerns. As an alternative, retrospective association studies are widely used for 
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initial selection of biomarker candidates (Gosho et al., 2012) and statistical 
modelling can be used to initially assess the predictive power of the selected 
genotypes and then select promising candidates for further clinical validation. 
Since there is insufficient evidence to currently support the use of any genetic 
biomarker of ovarian function/IVF-COS in a prospective study, we chose a 
retrospective study design to test whether genetic variants associated with 
reproductive aging could be potential candidates that could be considered as 
markers of ovarian function and IVF-COS. Therefore, in order to evaluate the 
predictive ability of selected genetic variants and used statistical models, we 
applied leave-one-out cross-validation modelling and compared the calculated 
R2 and AUC values to those obtained for original models. This approach was 
used both for models including cofactors and for models considering genetic 
factors without cofactors (clinical data). 
A model combining cofactors and all statistically significant genotypes 
explains 19% and 10% of the variation seen in mean antral follicle count 
(R2=0.194) and early follicular phase FSH levels (R2=0.108), respectively 
(Table 5). If cross-validation modelling is applied, the numbers decrease to 9% 
and 2%, respectively for mean follicle count (cross-validation R2=0.089) and 
early follicular phase FSH levels (cross-validation R2=0.019). However, without 
additional clinical data, the predictive power of statistically significant 
genotypes decreases remarkably for mean antral follicle count, but remains at 
~2–5% for early follicular phase FSH (R2=0.050, cross-validation R2=0.017). 
The relatively poor predictive ability for early follicular phase parameters can 
be explained by the limited number of participants with early follicular phase 
data.  
The prediction ability of significant genotypes together with selected clinical 
data for ovarian stimulation parameters is approximately 22–27% (~20% for 
cross-validation modelling), and without clinical data 4–13% (2–5% for cross-
validation modelling) for all studied characteristics. This indicates that the 
detected markers should have a predictive effect also in prospective studies, if 
combined with clinical data. The predictive power of selected genotypes 
without additional clinical data is similar to that reported for other complex 
traits, such as age at menopause (Stolk et al., 2012) and sex hormone-binding 
globulin levels (Coviello et al., 2012). 
In case of IVF treatment outcome parameters, a cross-validation model 
combining cofactors and selected (significant) genotypes yielded AUC<0.7 
(cross-validation AUC=0.63) for both biochemical and clinical pregnancies 
(Table 5). If clinical data was excluded from the model, the predictive value of 
only significant genotypes was modest (AUC<0.6, cross-validation AUC 
approximately 0.5). This relatively poor predictive ability for IVF treatment 
outcome parameters is most likely caused by the fact that a successful 
pregnancy requires a complex dialogue between the embryo and the mother, 
and the used models are probably insufficient to cover the intricate network of 
interactions.  
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Table 5. Results of cross-validation (CV) studies for selected genotypes with a 
statistically significant effect on studied traits in Study V. 
Analysed characteristic 




R2 / AUC CV 
R2 / AUC 
R2 / AUC CV 
R2 / AUC 
Early follicular phase parametersa    
Mean ovarian volumeb – – – – 
Mean antral follicle count 0.194 0.089 0.011 0.000 
Early follicular phase FSH 0.108 0.019 0.050 0.017 
Ovarian stimulation and outcome parametersa   
Total FSH 0.274 0.208 0.132 0.050 
Number of OPU follicles 0.248 0.194 0.071 0.028 
Number of retrieved oocytes 0.220 0.167 0.050 0.016 
Amount of FSH necessary 
for retrieving one oocyte 
0.242 0.199 0.043 0.015 
IVF treatment outcomec     
Biochemical pregnancies 0.652 0.626 0.574 0.486 
Clinical pregnancies 0.694 0.633 0.598 0.523 
FSH – follicle stimulating hormone, IVF – in vitro fertilisation, OPU – ovarian puncture 
a The squared correlation (R2) between observed and predicted values is reported  
b No genotypes with statistically significant effect 
c The area under the ROC-curve (AUC) is reported 
 
 
The study group for evaluating potential genetic biomarkers was quite diverse 
and included patients with various diagnoses and of different age. Nevertheless, 
patients with apparent ovarian dysfunction (PCOS and patients with only one 
ovary) were excluded from the study. Also, the potential markers of IVF-COS 
should be usable in everyday practice, which deals with very heterogeneous 
patients, thus searching for markers in a very homogeneous population of 
patients might not be very practical in the long run. In addition, all statistical 
analyses were adjusted for potential confounding factors, which means the 
reported results are valid regardless of, for example, the diagnosis for infertility, 
the age of the patient or the stimulation protocol used. Second, since this is a 
retrospective study, we were not able to assess whether the identified markers 
hold any actual predictive power in the clinical setting, therefore further studies 
are warranted for replicating and confirming the current results. Only if results 
from future studies are consistent with these presented here, a prospective 
clinical study can be conducted to determine the clinical validity of these 
marker candidates. However, results of statistical modelling demonstrated that 
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the detected markers most likely have an actual predictive effect that is more 
pronounced when combined with relevant clinical data. 
Taken together, these results highlight the fact that if in the future a genetic 
test is used for assessing ovarian function, it is most likely a panel test including 
tens of SNPs, because the variability seen in complex traits (such as those 
included in this study) is determined by a large number of genetic variants with 
a relatively small individual contribution, meaning that even variants that show 
very strong associations actually explain a very small part of the phenotypic 
variation, and the specificity and sensitivity of a single marker is insufficient for 
predictive clinical use (Moron et al., 2007). Furthermore, the statistical 
modelling performed in our study indicates that for optimal results, genotype 
data needs to be combined with clinical data and ideally, as proposed before 
(Wood and Rajkovic, 2013), evaluation of the ovarian function should 
incorporate genetic testing with relevant medical and family history, and 
clinical data, including serum markers and ultrasound imaging. Therefore great 
potential lies in integrating genetic and clinical data and creating predictive 
algorithms that could be then tested in the clinical setting. 
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CONCLUSIONS 
The main causes for female infertility in Estonia are TFI and PCOS. Both of 
these conditions are complex diseases, which means that they are caused by a 
combination of genetic and environmental factors and the individual 
contribution of each gene and genetic variant is small and individually 
insufficient to cause the disease. Numerous candidate gene association studies 
have been carried out for these diseases, but the results have been inconclusive. 
In the present thesis, the associations between two tandem repeats and PCOS 
were evaluated. The tandem repeats were selected based on the current 
knowledge about the pathogenesis of PCOS and were located in the genes for 
androgen receptor and insulin. In addition, nine genetic variants from four genes 
involved in immune response regulation were tested for association with TFI.  
The second main focus of this thesis revolved around potential genetic 
biomarkers that could be used for predicting ovarian function in natural and 
assisted reproduction. For this purpose, the genetic variants identified in studies 
of ovarian aging and in FSHB and FSHR genes were evaluated for association 
with ovarian function, controlled ovarian stimulation and IVF treatment 
parameters. The potential predictive ability of these markers was assessed using 
statistical modelling. 
  
Based on the results presented in this thesis, we can make the following 
conclusions: 
I. Genetic variation in insulin (INS VNTR) and androgen receptor (AR CAG) 
genes is not a susceptibility factor for PCOS among Estonian women. 
Furthermore, data from recent studies allow concluding that these two loci 
are not major susceptibility factors for the disease; however, they may 
modify certain aspects of the disease phenotype. 
II. According to the results presented in this thesis, approximately half of all 
TFI cases (48–59%) in Estonia can be categorised as having C. tracho-
matis-related TFI. Since infertility caused by infections is practically the 
only form of infertility that could be avoided, preventive measures and 
timely interventions could help to significantly reduce the number of 
women suffering from chlamydia-related infertility in Estonia. 
III. Genetic variants in CCR5 (CCR5delta32 deletion), TLR2 (Arg753Gln) and 
TLR4 (Asp299Gly, Thr399Ile) are not associated with TFI. However, 
several MBL2 genotypes were identified that may increase (HYA/HYA and 
MBL2 low-producing genotypes), or on the contrary, decrease (HYA/LYA) 
the susceptibility to TFI. Genetic variants in genes regulating immune 
response are good candidates for finding susceptibility loci for TFI.  
IV. Genetic variants related to ovarian aging (e. g. in RHBDL2 and SYCP2L) 
and in FSHB and FSHR genes are associated with ovarian function, COS 
and IVF treatment parameters.  
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V. Genetic variants related to ovarian aging are potential new biomarker 
candidates that could be considered as markers of ovarian function, COS 
and IVF treatment. However, the relatively poor predictive value of only 
genetic variants highlights the fact that various clinical and genetic 
biomarkers have to be combined to personalise COS. 
 
In conclusion, the studies in this thesis determined the prevalence of C. tracho-
matis-related TFI in Estonia and identified genetic variants that are associated 
with susceptibility to TFI in Estonian women. We also showed that genetic 
variants related to ovarian aging are associated with ovarian function, COS and 
IVF treatment parameters and could be considered as biomarker candidates if 
combined with clinical data. 
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SUMMARY IN ESTONIAN 
Geneetiline varieeruvus kui naisepoolse viljatuse  
eelsoodumuse mõjutaja ja võimalike uute biomarkerite allikas 
Edukaks raseduseks on tarvis naise reproduktiivtrakti erinevate osade – muna-
sarjade, munajuhade ning emaka laitmatut ning hästiajastatud koostööd. Kah-
juks on umbes 10%-l paaridest raskusi lapse saamisega ning naisepoolne 
viljatus on põhjuseks umbes 40%-l juhtudest, mis tähendab et neil naistel on see 
organite-vaheline koostöö häiritud. Kui mehepoolne viljatus on peamiselt 
tingitud sperma kvaliteedi langusest, siis naisepoolse viljatuse põhjused on väga 
mitmekesised ja selle taga võivad olla kahjustunud munajuhad, ovulatsiooni-
häired, endometrioos või emaka limaskesta probleemid. Eestis on naisepoolse 
viljatuse peamisteks põhjusteks tubaarne infertiilsus (TFI) ehk munajuhaviljatus 
ja polütsüstiliste munasarjade sündroom (PCOS), mis tähendab, et neil naistel 
on häirunud munasarjade ja munajuhade normaalne funktsioon.  
TFI korral on koekahjustuse tõttu tekkinud osaline või täielik munajuhade 
sulgus, mis takistab sugurakkude liikumist ja viljastumist munajuhades ja seega 
põhjustab probleeme järglaste saamisel. TFI peamiseks põhjuseks on väike-
vaagna põletikulised haigused, mis on eelkõige tingitud sugulisel teel levivatest 
patogeenidest – neist levinuim on Chlamydia trachomatis, mis põhjustab uro-
genitaalset klamüüdiainfektsiooni. Lisaks TFI-le võib klamüüdiainfektsiooni 
tagajärjel suureneda emakavälise raseduse risk. Eestis on TFI kehavälise 
viljastamise (IVF) ravi peamiseks näidustuseks, samas on urogenitaalse kla-
müüdiainfektsiooniga seotud TFI levimus Eesti viljatusravi patsientide seas 
teadmata. On leitud, et geneetiline varieeruvus mõjutab umbes 40% ulatuses 
seda, milline on immuunvastus klamüüdiainfektsioonile. Kuna inimeste vastu-
võtlikkus klamüüdiainfektsioonile, haiguse kulg ja lõpptulem sõltuvad paljudest 
erinevatest faktoritest, võib eeldada, et ka TFI riski mõjutavad mitmed geenid ja 
iga geeni ning geenivariandi individuaalne panus on üsna väike. TFI geneetiliste 
riskifaktorite uuringud on keskendunud kolmele põhilisele grupile – tsüto-
kiinide signaalradadega seotud geenid (IL-1B, IL-1RN, IL-6, IL-10, IL-12A, IL-
12B, TGFB, IFNG), antigeenide esitlemisega seotud geenid (HLA, MICA) ja 
mustriretseptorid (TLR2, TLR4, TLR9, CD14, CARD15/NOD2, MBL2), kuid 
väga väheseid seoseid on näidatud rohkem kui ühes uuringus ja seetõttu on TFI 
geneetiline taust veel küllaltki ebaselge. 
PCOS on hormonaalne häire, mille sagedus reproduktiivses eas naiste hulgas 
on umbes 10%. Haigusele on iseloomulik väga varieeruv kliiniline pilt, kuid 
sagedasemate sümptomite seas on menstruaaltsükli häired, kliiniline või bio-
keemiline hüperandrogenism, polütsüstiline munasarjade morfoloogia, üle-
kaalulisus ja insuliinresistentsus. Tihti käib haigusega kaasas ka viljatus, mis 
esineb umbes 40%-l PCOS patsientidest, lisaks on PCOS anovulatoorse vilja-
tuse peamine põhjus. Sündroomi kolm nn. nurgakivi – hüperandrogenism, 
ovulatsioonihäired ja insuliinresistentsusest tingitud hüperinsulinism on kõik 
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omavahel tugevas põhjus-tagajärg seoses ja koostoimel tekitavad haigusele 
iseloomuliku kliinilise pildi, kusjuures iga komponendi individuaalne panus 
võib olla väga erinev. PCOS-i riski mõjutavaid geene on otsitud peamiselt 
radadest, mis on seotud haiguse põhitunnustega, ja nii on kaheks enimuuritud 
variandiks androgeeni retseptori (AR) ja insuliini (INS) geenides paiknevad 
tandemjärjestused. Nagu paljudele geneetilistele uuringutele omane, on ka need 
tööd andnud vastukäivaid tulemusi. 
Eelpoolmainitud viljatusprobleemide peamiseks lahenduseks on IVF, mille 
käigus in vitro viljastatud embrüod siiratakse otse emakasse. Kahjuks on IVF 
ravi tulemuslikkus umbes 30% ühe ravitsükli kohta ja ravi edukuse määrab 
eelkõige munasarjade hormonaalse stimulatsiooni (COS) efektiivsus. See aga 
omakorda sõltub sellest, kuidas reageerivad munasarjad folliikuleid stimu-
leeriva hormooni (FSH) manustamisele.  
Aastate jooksul on palju uuritud nii mehe- kui naisepoolset viljatuse moleku-
laarset tausta ja on leitud mitmeid seoseid geneetiliste polümorfismide ja vilja-
tust põhjustavate haiguste vahel. Lisaks on jõutud järeldusele, et individuaalne 
geneetiline varieeruvus mõjutab ka üleüldist viljakust. Kuna individuaalne ge-
neetiline varieeruvus võiks olla ka hea allikas leidmaks reproduktiivfunktsiooni 
ja ehk isegi IVF ravi tulemuslikkust ennustavaid biomarkereid, on viimasel ajal 
paljud uuringud keskendunud selliste markerite leidmisele. Tänu nendele 
uuringutele teame me nüüd oluliselt rohkem viljakust mõjutavate geenide kohta, 
samas on veel palju ebaselget. Seetõttu soovisime ka oma uuringuga panustada 
viljakuse ja viljatuse geneetilise tausta selgitamisele. Nii PCOS kui TFI riski 
mõjutavate geneetiliste faktorite kindlaks tegemine võimaldaks oluliselt pare-
mini mõista nende haiguste tekkemehhanisme ja –põhjuseid. Info reproduktiiv-
funktsiooni geneetilise tausta kohta võiks olla abiks võimalike geneetiliste 




Käesoleva uurimistöö eesmärgiks oli hinnata seoseid erinevate geneetiliste 
variatsioonide ja PCOS ning TFI vahel. Lisaks uurisime mitmeid menopausi 
algusajaga või munasarja funktsiooniga seotud geneetilisi variatsioone, mis 
võiksid olla seotud ovariaalse reservi, munasarja stimulatsiooni ja IVF ravi 
tulemuslikkuse parameetritega.  
  
Töö alaeesmärgid olid järgnevad: 
I. Analüüsida, kas INS ja AR geenide varieeruvus on seotud PCOS geneetilise 
eelsoodumusega.  
II. Teha kindlaks urogenitaalse klamüüdiainfektsiooniga seotud TFI levimus 
Eesti viljatusravi patsientide seas.  
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III. Uurida, kas immuunvastusega seotud geenide polümorfismid võiksid olla 
seotud TFI geneetilise eelsoodumusega. 
IV. Analüüsida menopausi algusajaga seotud polümorfismide mõju munasarja 
funktsiooni, munasarja stimulatsiooni ning IVF ravi tulemuslikkust 
kajastavatele parameetritele.  
V. Hinnata, kas menopausi algusajaga seotud polümorfismid võiksid sobida 
munasarja funktsiooni, munasarja stimulatsiooni tulemuslikkuse ja IVF 
ravi tulemuslikkuse geneetilisteks biomarkeriteks. 
 
Materjal ja metoodika 
Uuringusse kaasati 439 erinevate viljatusdiagnoosidega naist, kellest moodustati 
uuringu eesmärkidest lähtuvalt väiksemaid uuringugruppe. Uuringus osalevatelt 
naistelt võeti vereproov, kust eraldati DNA ning seerum. Lisaks olid nende 
kohta olemas kliinilised andmed üldise tervisliku seisundi, viljatusanamneesi, 
munasarja stimulatsiooni ja IVF ravi tulemuslikkuse kohta. TFI uuringutesse 
kaasati lisaks TÜ Eesti Geenivaramu kaasabil 400 naist üldpopulatsioonist 
(neist 200 tõestatud viljakusega) ja 178 naist, kellel oli diagnoositud emaka-
väline rasedus, kuid kes teadaolevalt ei olnud viljatud. Nende naiste DNA-d, 
seerumid ja kliinilised andmed saadi TÜ Eesti Geenivaramust. 
Uuringute käigus genotüpiseeriti uuringus osalejatel kokku 47 geeni-
variatsiooni (tandemjärjestust, deletsiooni ja ühenukleotiidset polümorfismi ehk 
SNP-d) 22 erinevas geenis (INS, AR, CCR5, TLR2, TLR4, MBL2, FSHB, FSHR, 
TLK1, TMEM150B, NLRP11, MCM8, SYCP2L, PRIM1, FNDC4, ASH2L, 
UIMC1, KPNA3, RHBDL2, TDRD3, METAP1D, RNF44) ja geenivahelises 
alas. AR geeni varieeruvuse uuringus osalejatel määrati lisaks ka X-kromosoomi 
inaktivatsiooni muster.  
TFI uuringutes osalejatel määrati lisaks vereseerumist C. trachomatis-vasta-
sed IgG tüüpi antikehad, et teha kindlaks urogenitaalse klamüüdiinfektsiooniga 
seotud TFI levimus Eesti viljatusravi patsientide seas. 
 
Uurimistöö peamised tulemused ja järeldused 
I. Insuliini (INS VNTR) ja androgeeni retseptori (AR CAG) geenide 
varieeruvus ei mõjuta oluliselt PCOS haigestumise riski Eesti naiste seas. 
Lisaks lubavad hiljutiste uuringute tulemused kokkuvõtvalt järeldada, et 
need kaks variatsiooni ilmselt ei ole seotud PCOS geneetilise eelsoodu-
musega, küll aga ei saa välistada, et need variatsioonid võivad mõjutada 
juba avaldunud haiguse fenotüübi erinevaid aspekte.  
II. Vastavalt meie uuringu tulemustele on umbes pooled (48–59%) TFI juhud 
Eestis seotud urogenitaalse klamüüdiainfektsiooniga. Kuna infektsiooni-
dest tingitud viljatus on pea ainuke välditav viljatuse põhjus, võiksid asja-
kohased ennetusmeetmed ja õigeaegne ravi aidata oluliselt vähendada 
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urogenitaalsest klamüüdiainfektsioonist tingitud naisepoolse viljatuse 
esinemist Eestis. 
III. Varieeruvus CCR5 (CCR5delta32 deletsioon), TLR2 (Arg753Gln) and TLR4 
(Asp299Gly, Thr399Ile) geenides ei ole seotud TFI geneetilise eelsoodu-
musega. Samas leidsime mitmed immuunvastust mõjutavad MBL2 geno-
tüübid, mis võivad suurendada (kombineeritud genotüüp HYA/HYA ja 
MBL2 nn. madala tootlikkusega genotüübid), või vastupidi, vähendada 
(kombineeritud genotüüp HYA/LYA) TFI riski. Sellest tulenevalt võib 
järeldada, et immuunvastuse kujunemises osalevate valkude geenid on hea 
allikas infektsioonide/koekahjustusega seotud TFI geneetilise eelsoodu-
muse komponentide leidmiseks.  
IV. Meie uuring kinnitas, et menopausi algusajaga seotud geenides ja folliiku-
leid stimuleeriva hormooni β-subühiku (FSHB) ja selle retseptori (FSHR) 
geenides olevad SNPd on seotud munasarja funktsiooni, COS ja IVF ravi 
tulemuslikkuse parameetritega.  
V. Menopausi algusajaga seotud geneetilised variatsioonid on võimalikud 
uued biomarkeri kandidaadid, mida võiks kaaluda munasarja funktsiooni, 
COS ja IVF ravi tulemuslikkuse markeritena. Samas näitab ainult geneeti-
liste variantide kesine ennustusvõime seda, et ennustusvõime suurenda-
miseks tuleb geneetilisi variante kombineerida erinevate kliiniliste and-
metega.  
 
Kokkuvõttes näitavad käesoleva töö raames läbi viidud uuringud, et urogeni-
taalse klamüüdiainfektsiooniga seotud munajuhaviljatus on Eestis suhteliselt 
sage ja immuunvastust mõjutavate geenide varieeruvus võib mõjutada 
munajuhaviljatuse riski. Lisaks leidsime, et reproduktiivse vananemisega seotud 
geneetilised variatsioonid on seotud munasarja funktsiooni, COS ja IVF 
tulemuslikkuse parameetritega ning tulevikus võiks neid kaaluda võimalike 
biomarkeritena. Seega võivad uuringu tulemused mõjutada lastetuse ravi edasist 
arengut, kuna üha täienev infokogum reproduktiivfunktsiooni geneetilise tausta 
kohta on abiks võimalike geneetiliste biomarkerite valikul ning aitab muuta 
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